US20210122800A1 - Pro-drug peptide with improved pharmaceutical properties - Google Patents
Pro-drug peptide with improved pharmaceutical properties Download PDFInfo
- Publication number
- US20210122800A1 US20210122800A1 US17/135,627 US202017135627A US2021122800A1 US 20210122800 A1 US20210122800 A1 US 20210122800A1 US 202017135627 A US202017135627 A US 202017135627A US 2021122800 A1 US2021122800 A1 US 2021122800A1
- Authority
- US
- United States
- Prior art keywords
- pro
- peptide
- lys
- drug
- 8ado
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 226
- 229940002612 prodrug Drugs 0.000 title claims abstract description 127
- 239000000651 prodrug Substances 0.000 title claims abstract description 127
- 238000000034 method Methods 0.000 claims abstract description 100
- 150000001413 amino acids Chemical class 0.000 claims abstract description 70
- 239000000816 peptidomimetic Substances 0.000 claims abstract description 68
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 44
- 208000013016 Hypoglycemia Diseases 0.000 claims abstract description 33
- 230000004071 biological effect Effects 0.000 claims abstract description 28
- 230000002218 hypoglycaemic effect Effects 0.000 claims abstract description 28
- 201000010099 disease Diseases 0.000 claims abstract description 24
- 208000035475 disorder Diseases 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 230000001988 toxicity Effects 0.000 claims abstract description 16
- 231100000419 toxicity Toxicity 0.000 claims abstract description 16
- 238000001727 in vivo Methods 0.000 claims abstract description 15
- 231100001274 therapeutic index Toxicity 0.000 claims abstract description 14
- 238000010579 first pass effect Methods 0.000 claims abstract description 13
- 238000001179 sorption measurement Methods 0.000 claims abstract description 13
- 230000006872 improvement Effects 0.000 claims abstract description 11
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 94
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 33
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- RVQDZELMXZRSSI-IUCAKERBSA-N Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 RVQDZELMXZRSSI-IUCAKERBSA-N 0.000 claims description 18
- 239000003937 drug carrier Substances 0.000 claims description 17
- PBLZLIFKVPJDCO-UHFFFAOYSA-N 12-aminododecanoic acid Chemical compound NCCCCCCCCCCCC(O)=O PBLZLIFKVPJDCO-UHFFFAOYSA-N 0.000 claims description 16
- 150000001412 amines Chemical group 0.000 claims description 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
- YBTCBQBIJKGSJP-BQBZGAKWSA-N Glu-Pro Chemical compound OC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O YBTCBQBIJKGSJP-BQBZGAKWSA-N 0.000 claims description 9
- 108010065920 Insulin Lispro Proteins 0.000 claims description 9
- AIXUQKMMBQJZCU-IUCAKERBSA-N Lys-Pro Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O AIXUQKMMBQJZCU-IUCAKERBSA-N 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- RUVRGYVESPRHSZ-UHFFFAOYSA-N 2-[2-(2-azaniumylethoxy)ethoxy]acetate Chemical compound NCCOCCOCC(O)=O RUVRGYVESPRHSZ-UHFFFAOYSA-N 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 230000002862 amidating effect Effects 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 abstract description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 132
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 76
- 239000000203 mixture Substances 0.000 description 51
- 235000001014 amino acid Nutrition 0.000 description 45
- 229940024606 amino acid Drugs 0.000 description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 45
- 238000004128 high performance liquid chromatography Methods 0.000 description 35
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 33
- 102000004196 processed proteins & peptides Human genes 0.000 description 28
- 230000001225 therapeutic effect Effects 0.000 description 26
- 239000011347 resin Substances 0.000 description 25
- 229920005989 resin Polymers 0.000 description 25
- 108060003199 Glucagon Proteins 0.000 description 23
- 239000000243 solution Substances 0.000 description 23
- 102000051325 Glucagon Human genes 0.000 description 22
- 229960004666 glucagon Drugs 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 21
- 150000007523 nucleic acids Chemical class 0.000 description 19
- 239000003814 drug Substances 0.000 description 18
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 17
- 108020004707 nucleic acids Proteins 0.000 description 17
- 102000039446 nucleic acids Human genes 0.000 description 17
- 238000011894 semi-preparative HPLC Methods 0.000 description 17
- 239000012467 final product Substances 0.000 description 16
- 238000002514 liquid chromatography mass spectrum Methods 0.000 description 15
- 235000018977 lysine Nutrition 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- 239000004472 Lysine Substances 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 229920002527 Glycogen Polymers 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 229940096919 glycogen Drugs 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000003875 Wang resin Substances 0.000 description 5
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000012867 bioactive agent Substances 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 108091005601 modified peptides Proteins 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- -1 stereoisomers Chemical class 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- JPOKAKNGULMYHZ-UILVTTEASA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]-3-(4-hydroxyp Chemical compound C([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N)C1=CC=C(O)C=C1 JPOKAKNGULMYHZ-UILVTTEASA-N 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 4
- MUSGYEMSJUFFHT-UWABRSFTSA-N 2-[(4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-[[(2S,3S)-2-[[(2R)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]-methylcarbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13,17-dimethyl-28-[(1-methylindol-3-yl)methyl]-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](N)Cc1ccc(O)cc1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](C)NC(=O)CN(C)C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cn(C)c3ccccc23)NC(=O)[C@@H](NC1=O)C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)C(N)=O MUSGYEMSJUFFHT-UWABRSFTSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000002612 dispersion medium Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 238000010647 peptide synthesis reaction Methods 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 3
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 3
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 150000001860 citric acid derivatives Chemical class 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000007306 functionalization reaction Methods 0.000 description 3
- 230000004110 gluconeogenesis Effects 0.000 description 3
- 230000004121 glycogenesis Effects 0.000 description 3
- 230000004116 glycogenolysis Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007951 isotonicity adjuster Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000007492 two-way ANOVA Methods 0.000 description 3
- 238000000825 ultraviolet detection Methods 0.000 description 3
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000003070 absorption delaying agent Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 239000013066 combination product Substances 0.000 description 2
- 229940127555 combination product Drugs 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000008196 pharmacological composition Substances 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000000891 standard diet Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 2
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000005323 carbonate salts Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical class [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006218 nasal suppository Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 210000002571 pancreatic alpha cell Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- PARWUHTVGZSQPD-UHFFFAOYSA-N phenylsilane Chemical compound [SiH3]C1=CC=CC=C1 PARWUHTVGZSQPD-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000007921 solubility assay Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- QQWYQAQQADNEIC-RVDMUPIBSA-N tert-butyl [(z)-[cyano(phenyl)methylidene]amino] carbonate Chemical compound CC(C)(C)OC(=O)O\N=C(/C#N)C1=CC=CC=C1 QQWYQAQQADNEIC-RVDMUPIBSA-N 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
Definitions
- the present disclosure relates to pro-drug peptides, making the same, and using the same for treating diseases.
- the present disclosure relates to a pro-drug peptide that includes a parent peptide or peptidomimetic and a pro-drug portion that includes at least two amino acids that are cleaved in vivo, releasing the parent peptide or peptidomimetic.
- Pro-drugs are compounds that are metabolized by the subject after administration to form a pharmaceutically active compound or drug.
- the general object of a prodrug is to mask undesirable properties. For example, irritation or pain after local administration, chemical instability, low target selectively, low solubility in water or lipid membranes, toxicity, pre-systemic metabolism, among others.
- pro-drug modifications are designed to optimize, inter alia, adsorption, distribution, metabolism, excretion, and/or unwanted toxicity of a parent compound or drug.
- prodrugs are used, inter alia, to optimize therapeutic index, decrease toxicity, improve adsorption, decrease pre-systemic metabolism, improve solubility and improve chemical stability.
- Pro-drugs can be classified into two general categories: Type 1 and Type II pro-drugs.
- Type I pro-drugs e.g., anti-viral nucleoside analogs
- Type II pro-drugs e.g., salicin
- Type II pro-drugs are bioactivated extracellularly with Type IIA being converted in the gastrointestinal fluid
- Type IIB being converted in extracellular fluid compartments (e.g., circulatory system)
- Type IIC being converted near or inside therapeutic targets/cells.
- Glucagon is a 29 amino acid peptide hormone that is produced by pancreatic alpha-cells in response to low blood glucose levels, thereby stimulating glycogenolysis (i.e., the breakdown of glycogen [n] to glucose-6-phosphate and glycogen [n ⁇ 1]) and gluconeogenesis (i.e., the synthesis of glucose from non-carbohydrate carbon substrates), and inhibiting glycogenesis (i.e., the synthesis of glycogen from sugar).
- glycogenolysis i.e., the breakdown of glycogen [n] to glucose-6-phosphate and glycogen [n ⁇ 1]
- gluconeogenesis i.e., the synthesis of glucose from non-carbohydrate carbon substrates
- glycogenesis i.e., the synthesis of glycogen from sugar
- insulin-dependent diabetes is a well-known risk factor for severe hypoglycaemia, where blood glucose levels can fall below 50 mg/dl.
- the standard treatment for hypoglycaemia (such as severe insulin-induced hypoglycaemia) is acute subcutaneous administration of glucagon. Because of glucagon's poor chemical stability, however, glucagon is supplied in a lyophilized powder that is prepared immediately prior to administration. Furthermore, because of glucagon's poor aqueous solubility at physiological pH, the solution for administration is prepared with dilute aqueous hydrochloric acid. Also because of glycogen's chemical instability, the dilute hydrochloric acid prepared glucagon must be used immediately.
- the present description provides therapeutic compositions and methods of making and using the same that are based on the surprising and unexpected discovery that chemically modified peptides as described herein have improvement for at least one biological property (such as, a biological property whose improvement enhances its therapeutic effect) relative to a parent peptide or peptidomimetic (i.e., the unmodified peptide).
- the modified peptides or peptidomimetic as described herein include a pro-drug portion that is cleaved in vivo, after administration, to release the parent peptide or peptidomimetic.
- the described peptides and compositions comprising effective amounts of the same are effective for treating, preventing and/or ameliorating the symptoms of diseases and disorders that are treated, prevented, or ameliorated by the release of the parent peptide or peptidomimetic (for example, the release of glucagon or an analog thereof to treat a hypoclycemia related disease or disorder). Accordingly, in certain additional aspects, the disclosure provides methods of making and using the described peptides and compositions comprising the same for the treatment, prevention and/or amelioration of the symptoms a hypoglycemia relates disease or disorder.
- the present disclosure provides a pro-drug peptide or a salt thereof (e.g., a pharmaceutical salt thereof) having improvement for at least one biological property relative to a parent peptide or peptidomimetic, wherein the biological property is selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism, the pro-drug peptide comprising the following structure:
- pep is the parent peptide or peptidomimetic
- Z is a pro-drug portion, e.g., an amino acid sequence of n amino acids, wherein Z is cleaved in vivo releasing pep
- n is an integer ⁇ 2 amino acids.
- the Z has the following structure: (Glu-Pro) m or (Lys-Pro) X , wherein X is an integer ⁇ 1.
- At least the first Lys of Z is functionalized with a soluble compound or moiety.
- At least two Lys of Z are functionalized with a soluble compound or moiety.
- the Z comprises two amino acids, and the first amino acid is functionalized with a soluble compound or moiety.
- the soluble compound is hydrophilic or soluble in aqueous solution.
- the Z is selected from the group consisting of EP, KP, EPEP, KPKP, EPEPEP, and KPKPKP.
- the first amino acid of Z is functionalized with a soluble compound or moiety comprising: 12-aminododecanoic acid (Ado), Ado-Ado-(Lys) m , 8-amino-3,6-dioxaoctanoic acid (8Ado), 8Ado-8Ado-(Lys) m , (Lys) m , or (Pro-Lys) m , wherein m is an integer from 0-10.
- At least two Lys of Z are functionalized with a soluble compound or moiety comprising: Ado, Ado-Ado-(Lys) m , 8Ado, 8Ado-8Ado-(Lys) m , (Lys) m , or (Pro-Lys) m . wherein m is an integer from 0-10.
- the c-terminus of the peptide is amine modified or amidated.
- the parent peptide or peptidomimetic has an amino acid sequence that is at least 85% identical to a sequence selected from the group consisting of SEQ ID NO: 1 (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) and SEQ ID NO: 2 (HSQGTFTSDYSKYLDSRRAQDFVQWLLNT).
- a pharmaceutical composition comprising an effective amount of at least one pro-drug of the present disclosure, and a pharmaceutically acceptable excipient or carrier.
- the description provides therapeutic compositions comprising an effective amount of at least one pro-drug peptide of the present disclosure, and an effective amount of at least one additional bioactive agent.
- the composition further comprises an excipient or carrier as described herein.
- the present disclosure provides a method of treating or preventing hypoglycemia or a hypoglycemia related disorder or disease.
- the method comprises: administering an effective amount of the pro-drug peptide of the present disclosure or the pharmaceutical composition of the present disclosure, wherein the pro-drug peptide is effective at treating or preventing hypoglycemia or the hypoglycemia related disorder or disease.
- the present disclosure provides a method of preparing a pro-drug peptide or salt thereof (e.g., a pharmaceutical salt thereof) having improved biological property or properties (e.g., at least one biological property selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism) relative to a parent peptide or peptidomimetic.
- a pro-drug peptide or salt thereof e.g., a pharmaceutical salt thereof
- improved biological property or properties e.g., at least one biological property selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism
- the method comprises: adding a pro-drug portion to the parent peptide or peptidomimetic (e.g., synthesizing the pro-drug portion and the peptide or peptidomimetic as a contiguous sequence by any method known or that becomes known to those skilled in the art), wherein the pro-drug portion comprises ⁇ 2 amino acids that are cleaved in vivo releasing the peptide or peptidomimetic.
- a pro-drug portion to the parent peptide or peptidomimetic (e.g., synthesizing the pro-drug portion and the peptide or peptidomimetic as a contiguous sequence by any method known or that becomes known to those skilled in the art), wherein the pro-drug portion comprises ⁇ 2 amino acids that are cleaved in vivo releasing the peptide or peptidomimetic.
- the pro-drug portion is located at the amino-terminus of the parent peptide or peptidomimetic. In other embodiments, the pro-drug portion is located at the carboxyl-terminus of the parent peptide or peptidomimetic.
- the pro-drug portion has the following structure: (Glu-Pro) m or (Lys-Pro) X , wherein X is an integer ⁇ 1.
- At least the first Lys of the pro-drug portion is functionalized with a soluble compound.
- At least two Lys of the pro-drug portion are functionalized with a soluble compound.
- the pro-drug portion comprises two amino acids, and the first amino acid is functionalized with a soluble compound.
- the soluble compound is aqueously soluble.
- the pro-drug portion is selected from the group consisting of EP, KP, EPEP, KPKP, EPEPEP, and KPKPKP.
- the first amino acid of the pro-drug portion is functionalized with a soluble compound or moiety comprising: 12-aminododecanoic acid (Ado), Ado-Ado-(Lys) m , 8-amino-3,6-dioxaoctanoic acid (8Ado), 8Ado-8Ado-(Lys) m , (Lys) m , or (Pro-Lys) m . wherein m is an integer from 0-10.
- At least two Lys of the pro-drug portion is functionalized with a soluble compound or moiety comprising: Ado, Ado-Ado-(Lys) m , 8Ado, 8Ado-8Ado-(Lys) m , (Lys) m , or (Pro-Lys) m , wherein m is an integer from 0-10.
- the parent peptide or peptidomimetic has an amino acid sequence that is at least 85% identical to a sequence selected from the group consisting of SEQ ID NO: 1 (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) and SEQ ID NO: 2 (HSQGTFTSDYSKYLDSRRAQDFVQWLLNT).
- the method further comprises amidating the c-terminus of the peptide.
- the method further comprises modifying the c-terminus of the protein with an amine.
- FIG. 1 Illustrates and aligns peptides 1-9, which includes a parent peptide and several exemplary pro-drugs including the same.
- FIG. 2 Illustrates an exemplary functionalization of a Lys with Lys-Lys-Lys-Lys-Lys-Lys-Lys, wherein when the Lys is at the N-terminus one skilled in the art appreciates that a hydrogen is bound to the nitrogen on the left side of the chemical structure.
- FIG. 3 Illustrates an exemplary functionalization of a Lys with 8Ado-8Ado, wherein when K* is the N-terminus one skilled in the art appreciates that a hydrogen is bound to the nitrogen on the left side of the chemical structure.
- FIG. 4 Illustrates an exemplary functionalization of a Lys with Ado-Ado, wherein when K* is the N-terminus one skilled in the art appreciates that a hydrogen is bound to the nitrogen on the left side of the chemical structure.
- FIG. 5 Stability of peptide 3 (1 mg/mL) in PBS (phosphate buffered saline) at room temperature over 10 days.
- FIG. 6 Stability of peptide 4 (1 mg/mL) in water at room temperature over 46 days.
- FIG. 7 Stability of peptide 4 (1 mg/mL) in physiological serum at room temperature over 18 days.
- FIG. 8 Stability of peptide 5 (1 mg/mL) in physiological serum at 4° C. over 7 days.
- FIG. 9 Stability of peptide 5 (1 mg/mL) in physiological serum at room temperature over 18 days.
- FIG. 11A and FIG. 11B Illustrates and aligns of peptides 10-25, which includes the parent peptide and several exemplary pro-drugs including the same.
- (B) Illustrates the chemical structure of the modified lysines illustrated in FIG. 11A , wherein when K* is the N-terminus one skilled in the art appreciates that a hydrogen is bound to the nitrogen on the left side of the chemical structure.
- FIG. 14A and FIG. 14B (A) High-performance liquid chromatography (HPLC) profile of peptide 10 (10-100%; CH 3 CN 0.1% trifluoroacetic acid (TFA) in H 2 O 0.1% TFA, 10 min, C18). (B) liquid chromatography-mass spectrometry (LC-MS) spectrum of peptide 10.
- FIG. 15A and FIG. 15B (A) HPLC profile of peptide 11 (10-100%; CH 3 CN 0.1% TFA in H 2 O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 11.
- FIG. 16A and FIG. 16B (A) HPLC profile of peptide 12 (10-100%; CH 3 CN 0.1% TFA in H 2 O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 12.
- FIG. 17A and FIG. 17B (A) HPLC profile of peptide 13 (10-100%; CH 3 CN 0.1% TFA in H 2 O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 13.
- FIG. 18A and FIG. 18B (A) HPLC profile of peptide 14 (10-100%; CH 3 CN 0.1% TFA in H 2 O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 14.
- FIG. 19A and FIG. 19B (A) HPLC profile of peptide 15 (10-100%; CH 3 CN 0.1% TFA in H 2 O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 15.
- FIG. 20A and FIG. 20B (A) HPLC profile of peptide 16 (10-100%; CH 3 CN 0.1% TFA in H 2 O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 16.
- FIG. 21A and FIG. 21B (A) HPLC profile of peptide 17 (10-100%; CH 3 CN 0.1% TFA in H 2 O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 17.
- FIG. 22A and FIG. 22B (A) HPLC profile of peptide 18 (10-100%; CH 3 CN 0.1% TFA in H 2 O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 18.
- FIG. 23A and FIG. 23B (A) HPLC profile of peptide 19 (10-100%; CH 3 CN 0.1% TFA in H 2 O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 19.
- FIG. 24A and FIG. 24B (A) HPLC profile of peptide 20 (10-100%; CH 3 CN 0.1% TFA in H 2 O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 20.
- FIG. 25A and FIG. 25B (A) HPLC profile of peptide 21 (10-100%; CH 3 CN 0.1% TFA in H 2 O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 21.
- FIG. 26A and FIG. 26B (A) HPLC profile of peptide 22 (10-100%; CH 3 CN 0.1% TFA in H 2 O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 22.
- FIG. 27A and FIG. 27B (A) HPLC profile of peptide 23 (10-100%; CH 3 CN 0.1% TFA in H 2 O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 23.
- FIG. 28A and FIG. 28B (A) HPLC profile of peptide 24 (10-100%; CH 3 CN 0.1% TFA in H 2 O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 24.
- FIG. 29A and FIG. 29B (A) HPLC profile of peptide 25 (10-100%; CH 3 CN 0.1% TFA in H 2 O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 25.
- a reference to “A and/or B”, when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.
- the phrase “at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from anyone or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements.
- This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase “at least one” refers, whether related or unrelated to those elements specifically identified.
- “at least one of A and B” can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.
- co-administration and “co-administering” or “combination therapy” refer to both concurrent administration (administration of two or more therapeutic agents at the same time) and time varied administration (administration of one or more therapeutic agents at a time different from that of the administration of an additional therapeutic agent or agents), as long as the therapeutic agents are present in the patient to some extent, preferably at effective amounts, at the same time.
- one or more of the present compounds described herein are coadministered in combination with at least one additional bioactive agent, e.g. an agent that stimulates glycogenolysis, stimulates gluconeogenesis, and/or inhibiting glycogenesis.
- the co-administration of compounds results in synergistic activity and/or therapy, including anti-hypoclycemic activity.
- compound refers to any specific chemical compound disclosed herein and includes tautomers, regioisomers, geometric isomers, and where applicable, stereoisomers, including optical isomers (enantiomers) and other steroisomers (diastereomers) thereof, as well as pharmaceutically acceptable salts and derivatives (including prodrug forms) thereof where applicable, in context.
- the term compound generally refers to a single compound, but also may include other compounds such as stereoisomers, regioisomers and/or optical isomers (including racemic mixtures) as well as specific enantiomers or enantiomerically enriched mixtures of disclosed compounds.
- the term also refers, in context to prodrug forms of compounds which have been modified to facilitate the administration and delivery of compounds to a site of activity. It is noted that in describing the present compounds, numerous substituents and variables associated with same, among others, are described. It is understood by those of ordinary skill that molecules which are described herein are stable compounds as generally described hereunder.
- derivatives can mean, but is in no way limited to, chemical compositions, for example, nucleic acids, nucleotides, polypeptides or amino acids, formed from the native compounds either directly, by modification, or by partial substitution.
- analogs can mean, but is in no way limited to, chemical compositions, for example, nucleic acids, nucleotides, polypeptides or amino acids that have a structure similar to, but not identical to, the native compound.
- an amount/dose can mean, but is in no way limited to, that amount/dose of the active pharmaceutical ingredient sufficient to prevent, inhibit the occurrence, ameliorate, delay or treat (alleviate a symptom to some extent, preferably all) at least one symptom of a condition, disorder or disease state.
- the effective amount depends on the type of disease, the composition used, the route of administration, the type of mammal being treated, the physical characteristics of the specific mammal under consideration, concurrent medication, and other factors which those skilled in the medical arts will recognize. Generally, an amount between 0.1 mg/kg and 1000 mg/kg body weight/day of active ingredients is administered dependent upon potency of the agent.
- Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
- the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50.
- Compounds that exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
- the data obtained from the cell culture assays and animal studies can be used in formulating a range of dosages for use in humans.
- the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity.
- the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
- the therapeutically effective dose can be estimated initially from cell culture assays.
- a dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture.
- IC50 i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms
- levels in plasma may be measured, for example, by high performance liquid chromatography.
- composition can mean, but is in no way limited to, a composition or formulation that allows for the effective distribution of an agent provided by the present disclosure, which is in a form suitable for administration to the physical location most suitable for their desired activity, e.g., systemic administration.
- pharmaceutically acceptable or “pharmacologically acceptable” can mean, but is in no way limited to, entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, or a human, as appropriate.
- pharmaceutically acceptable carrier or “pharmacologically acceptable carrier” can mean, but is in no way limited to, any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, ringer's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
- systemic administration refers to a route of administration that is, e.g., enteral or parenteral, and results in the systemic distribution of an agent leading to systemic absorption or accumulation of drugs in the blood stream followed by distribution throughout the entire body.
- Suitable forms depend upon the use or the route of entry, for example oral, transdermal, or by injection. Such forms should not prevent the composition or formulation from reaching a target cell (i.e., a cell to which the negatively charged polymer is desired to be delivered to).
- pharmacological compositions injected into the blood stream should be soluble.
- Other factors are known in the art, and include considerations such as toxicity and forms which prevent the composition or formulation from exerting its effect.
- Administration routes which lead to systemic absorption include, without limitations: intravenous, subcutaneous, intraperitoneal, inhalation, oral, intrapulmonary and intramuscular.
- the rate of entry of a drug into the circulation has been shown to be a function of molecular weight or size.
- the use of a liposome or other drug carrier comprising the compounds of the instant invention can potentially localize the drug, for example, in certain tissue types, such as the tissues of the reticular endothelial system (RES).
- RES reticular endothelial system
- a liposome formulation which can facilitate the association of drug with the surface of cells, such as, lymphocytes and macrophages is also useful.
- local administration refers to a route of administration in which the agent is delivered to a site that is apposite or proximal, e.g., within about 10 cm, to the site of the lesion or disease.
- nucleic acid alterations refers to the substitution, deletion or addition of nucleic acids that alter, add or delete a single amino acid or a small number of amino acids in a coding sequence where the nucleic acid alterations result in the substitution of a chemically similar amino acid.
- Amino acids that may serve as conservative substitutions for each other include the following: Basic: Arginine (R), Lysine (K), Histidine (H); Acidic: Aspartic acid (D), Glutamic acid (E), Asparagine (N), Glutamine (Q); hydrophilic: Glycine (G), Alanine (A), Valine (V), Leucine (L), Isoleucine (I); Hydrophobic: Phenylalanine (F), Tyrosine (Y), Tryptophan (W); Sulfur-containing: Methionine (M), Cysteine (C).
- sequences that differ by conservative variations are generally homologous.
- homologous nucleic acid or amino acid sequence has 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% sequence similarity or identity to the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2, respectively.
- “Homologs” can be naturally occurring, or created by artificial synthesis of one or more nucleic acids (or amino acids resulting therefrom) having related sequences, or by modification of one or more nucleic acid (or amino acids that result therefrom) to produce related nucleic acids. Nucleic acids (and thus the resultant amino acid sequence) are homologous when they are derived, naturally or artificially, from a common ancestor sequence (e.g., orthologs or paralogs). If the homology between two nucleic acids is not expressly described, homology can be inferred by a nucleic acid comparison between two or more sequences (including the amino acid sequences).
- nucleic acid sequences are homologous if the sequences are sufficiently similar to allow recombination and/or hybridization under low stringency conditions.
- polypeptides are regarded as homologous if their nucleic acid sequences are sufficiently similar to allow recombination or hybridization under low stringency conditions, and optionally they demonstrate similar activity as the parent peptide, and optionally they can be recognized by (i.e., cross-react with) an antibody specific for an epitope contained within the amino acid sequence of the patent peptide, e.g., at least one of SEQ ID NO: 1 or SEQ ID NO: 2.
- the term “cell” can mean, but is in no way limited to, it's usual biological sense, and does not refer to an entire multicellular organism.
- the cell can, for example, be in vivo, in vitro or ex vivo, e.g., in cell culture, or present in a multicellular organism, including, e.g., birds, plants and mammals such as humans, cows, sheep, apes, monkeys, swine, dogs, and cats.
- the cell can be prokaryotic (e.g., bacterial cell) or eukaryotic (e.g., mammalian or plant cell).
- host cell can mean, but is in no way limited to, a cell that might be used to carry a heterologous nucleic acid, or expresses a peptide or protein encoded by a heterologous nucleic acid.
- a host cell can contain genes that are not found within the native (non-recombinant) form of the cell, genes found in the native form of the cell where the genes are modified and re-introduced into the cell by artificial means, or a nucleic acid endogenous to the cell that has been artificially modified without removing the nucleic acid from the cell.
- a host cell may be eukaryotic or prokaryotic.
- a “host cell” can also be one in which the endogenous genes or promoters or both have been modified to produce one or more of the polypeptide components of the complex of the invention.
- patient or “subject” is used throughout the specification to describe an animal, preferably a human or a domesticated animal, to whom treatment, including prophylactic treatment, with the compositions according to the present invention is provided.
- patient refers to that specific animal, including a domesticated animal such as a dog or cat or a farm animal such as a horse, cow, sheep, etc.
- patient refers to a human patient unless otherwise stated or implied from the context of the use of the term.
- a therapeutically effective amount or dose includes a dose of a drug that is capable of achieving a therapeutic effect in a subject in need thereof.
- a therapeutically effective amount of a drug can be the amount that is capable of preventing or relieving one or more symptoms associated with a disease or disorder, e.g., tissue injury or muscle-related disease or disorder.
- the exact amount can be ascertainable by one skilled in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols.
- kits are any manufacture (e.g. a package or container) comprising at least one pro-drug peptide of the present disclosure or pharmaceutical composition of the present disclosure.
- the manufacture may be promoted, distributed, or sold as a unit for performing the methods of the present disclosure.
- the kits of the present disclosure may preferably contain instructions which describe a suitable administration method.
- Such kits can be conveniently used, e.g., in clinical settings, to treat or ameliorate patients exhibiting symptoms of disease or disorder (such as, a hypoglycemia or hypoglycemia relates disease or disorder).
- the present description provides therapeutic compositions and methods of using the same that are based on the surprising and unexpected discovery that the chemically modified peptides or peptidomimetics as described herein have improved one or more biological properties.
- the pro-drug peptide of the present disclosure includes improvement in at least one biological property (such as, a biological property whose improvement enhances its therapeutic effect) relative to a parent peptide or peptidomimetic (i.e., the unmodified peptide).
- the modified peptides (i.e., the pro-drug peptides) of the present disclosure include a pro-drug portion that is cleaved in vivo, after administration, to release the parent peptide or peptidomimetic.
- DPP4 dipeptidyl peptidase-4
- CD26 cluster of differentiation 26
- DDP4 dipeptidyl peptidase-4
- CD26 cluster of differentiation 26
- DDP4 which is a serine exopeptidase expressed on the surface of most cell types and that cleaves X-proline dipeptides from the N-terminus of polypeptides, cleaves the pro-drug portion in vivo to release the patent peptide or peptidomimetic.
- other enzyme or enzymes may be involved in or facilitate, alone or in combination with DDP4, in the release of the parent peptide or peptidomimetic from the pro-drug form.
- Pharmacological peptides or peptidomimetics display a number of advantageous properties that makes them excellent therapeutics, notably for autoimmune diseases.
- peptides or peptidomimetics selected as active components of pharmaceutical compositions are characterized by their stability and robustness, easy handling, the relatively low doses that have to be administrated to patients and their cost, which remains reasonable with regard to most biologics.
- Short peptides are not immunogenic per se, which is another considerable advantage for treating patients with chronic autoimmune diseases (Schall and Muller, 2014).
- the present description provides therapeutic compositions and methods of using the same that are based on the surprising and unexpected discovery that chemically modified peptides or peptidomimetics as described herein create pro-drugs with improved biological properties that enhance the therapeutic effect of the parent peptide or peptidomimetic.
- the present disclosure provides a pro-drug peptide or a salt thereof (e.g., a pharmaceutical salt thereof) having improvement for at least one biological property relative to a parent peptide or peptidomimetic, wherein the biological property is selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism, the pro-drug peptide comprising the following structure:
- pep is the parent peptide or peptidomimetic
- Z is a pro-drug portion, e.g., an amino acid sequence of n amino acids, wherein Z (pro-drug portion) is cleaved in vivo releasing pep
- n is an integer of ⁇ 2 amino acids (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more).
- the pro-drug portion (Z) can have the following structure: (Glu-Pro) m or (Lys-Pro) X , wherein X is an integer ⁇ 1 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more).
- Z can be Glu-Pro, Lys-Pro, Glu-Pro-Glu-Pro (SEQ ID NO: 30), Lys-Pro-Lys-Pro (SEQ ID NO: 11), Glu-Pro-Glu-Pro-Glu-Pro (SEQ ID NO: 31), and Lys-Pro-Lys-Pro-Lys-Pro (SEQ ID NO: 12).
- the Z comprises two amino acids, and the first amino acid is functionalized with a soluble compound as described herein.
- At least the first amino acid (e.g., Lys) of the pro-drug portion e.g., the first amino acid, the third amino acid, the fifth amino acid, the seventh amino acid, or a combination thereof, such as the first and third amino acid (e.g., first and second Lys); the first and fifth amino acid (e.g., first and third Lys); the first, third, and fifth amino acid (e.g., first, second, and third Lys; etc.
- the first amino acid (e.g., Lys) of the pro-drug portion e.g., the first amino acid, the third amino acid, the fifth amino acid, the seventh amino acid, or a combination thereof, such as the first and third amino acid (e.g., first and second Lys); the first and fifth amino acid (e.g., first and third Lys); the first, third, and fifth amino acid (e.g., first, second, and third Lys; etc.)
- the soluble compound may be aqueously soluble.
- the pro-drug portion may be functionalized with a soluble compound comprising: 12-aminododecanoic acid (Ado), Ado-Ado-(Lys) m , 8-amino-3,6-dioxaoctanoic acid (8Ado), 8Ado-8Ado-(Lys) m , (Lys) m (e.g., [Lys] 6 ; SEQ ID NO: 13), or (Pro-Lys) m (e.g., [Pro-Lys] 3 , SEQ ID NO: 29), wherein m is an integer from 0-10.
- Lys of Z are functionalized with a soluble compound, which may comprise: Ado, Ado-Ado-(Lys) m , 8Ado, 8Ado-8Ado-(Lys) m , (Lys) m (e.g., [Lys] 6 ; SEQ ID NO: 13), or (Pro-Lys) m (e.g., [Pro-Lys] 3 , SEQ ID NO: 29), wherein m is an integer from 0-10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10).
- a soluble compound which may comprise: Ado, Ado-Ado-(Lys) m , 8Ado, 8Ado-8Ado-(Lys) m , (Lys) m (e.g., [Lys] 6 ; SEQ ID NO: 13), or (Pro-Lys) m (e.g., [Pro-Lys]
- the peptide may be amine modified at the c-terminus or the c-terminus of the peptide may be amidated.
- the parent peptide or peptidomimetic can be any peptide or peptidomimetic one wishes to improve at least one biological property that enhances the therapeutic effect of the peptide or peptidomimetic.
- the parent peptide or peptidomimetic may have an amino acid sequence that is at least 60% identical (e.g., at least 65%, 70%, 75%, 80%, 85%, 90%, 92.5%, 95%, 97.5%, 98%, 99%, or 100% identical) to glucagon.
- the parent peptide or peptidomimetic has an amino acid sequence that is at least 60% identical (e.g., at least 65%, 70%, 75%, 80%, 85%, 90%, 92.5%, 95%, 97.5%, 98%, 99%, or 100% identical) to a sequence selected from the group consisting of SEQ ID NO: 1 (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) and SEQ ID NO: 2 (HSQGTFTSDYSKYLDSRRAQDFVQWLLNT).
- a pharmaceutical composition that comprises at least one pro-drug peptide of the present disclosure, and a pharmaceutically acceptable excipient or carrier.
- the description provides therapeutic compositions comprising at least one pro-drug peptide of the present disclosure, and at least one additional bioactive agent.
- the additional bioactive agent can be any agent that stimulates glycogenolysis, stimulates gluconeogenesis, and/or inhibiting glycogenesis.
- the composition further comprises an excipient (e.g., a pharmaceutically acceptable excipient) or carrier (e.g., pharmaceutically acceptable carrier) as described herein.
- the present disclosure provides a method of treating or preventing hypoglycemia or a hypoglycemia related disorder or disease.
- the method comprises: administering an effective amount of the pro-drug peptide of the present disclosure or the pharmaceutical composition of the present disclosure, wherein the pro-drug peptide comprises a parent peptide or peptidomimetic that has an amino acid sequence that has at least 60% identity (e.g., at least 65%, 70%, 75%, 80%, 85%, 90%, 92.5%, 95%, 97.5%, 98%, 99%, or 100% identical) with glycogen.
- the pro-drug peptide comprises a parent peptide or peptidomimetic that has an amino acid sequence that has at least 60% identity (e.g., at least 65%, 70%, 75%, 80%, 85%, 90%, 92.5%, 95%, 97.5%, 98%, 99%, or 100% identical) with glycogen.
- the peptide or peptidomimetic may comprise an amino acid sequence that has at least 60% identity (e.g., at least 65%, 70%, 75%, 80%, 85%, 90%, 92.5%, 95%, 97.5%, 98%, 99%, or 100% identical)with the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, and the pro-drug is effective at treating or preventing hypoglycemia or the hypoglycemia related disorder or disease.
- 60% identity e.g., at least 65%, 70%, 75%, 80%, 85%, 90%, 92.5%, 95%, 97.5%, 98%, 99%, or 100% identical
- the present disclosure provides a method of preparing a pro-drug peptide or salt thereof (e.g., a pharmaceutical salt thereof) having improved biological property or properties (e.g., at least one biological property selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism) relative to a parent peptide or peptidomimetic.
- a pro-drug peptide or salt thereof e.g., a pharmaceutical salt thereof
- improved biological property or properties e.g., at least one biological property selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism
- the method comprises: adding a pro-drug portion to the parent peptide or peptidomimetic (e.g., synthesizing the prodrug peptide by solid-phase synthesis or liquid-phase synthesis, wherein the pro-drug portion is located at the amino-terminus or the carboxyl-terminus of the parent peptide or peptidomimetic), wherein the pro-drug portion comprises ⁇ 2 amino acids that are cleaved in vivo releasing the peptide or peptidomimetic.
- a pro-drug portion e.g., synthesizing the prodrug peptide by solid-phase synthesis or liquid-phase synthesis, wherein the pro-drug portion is located at the amino-terminus or the carboxyl-terminus of the parent peptide or peptidomimetic
- the pro-drug portion comprises ⁇ 2 amino acids that are cleaved in vivo releasing the peptide or peptidomimetic.
- the pro-drug portion has the following structure: (Glu-Pro) m or (Lys-Pro) X , wherein X is an integer ⁇ 1 (e.g., X is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more).
- the pro-drug portion may be selected from the group consisting of EP, KP, EPEP, KPKP, EPEPEP, and KPKPKP.
- the first Lys of the pro-drug portion is functionalized with a soluble compound or moiety.
- at least two Lys of the pro-drug portion are functionalized with a soluble compound or moiety.
- the pro-drug portion comprises two amino acids, and the first amino acid is functionalized with a soluble compound or moiety.
- the soluble compound or moiety may be hydrophilic or soluble in aqueous solution.
- the first amino acid or the first Lys of the pro-drug portion may be functionalized with a soluble compound or moiety comprising: 12-aminododecanoic acid (Ado), Ado-Ado-(Lys) m , 8-amino-3,6-dioxaoctanoic acid (8Ado), 8Ado-8Ado-(Lys) m , (Lys) m , or (Pro-Lys) m . wherein m is an integer from 0-10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10).
- At least two Lys of the pro-drug portion may be functionalized with a soluble compound comprising: Ado, Ado-Ado-(Lys) m , 8Ado, 8Ado-8Ado-(Lys) m , (Lys) m , or (Pro-Lys) m , wherein m is an integer from 0-10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10).
- the parent peptide or peptidomimetic may be any peptide or peptidomemtic that has therapeutic activity/effect. That is, the pro-drug portion (Z) of the present disclosure may be utilized on the amino-terminus or carboxyl-terminus of any peptide or peptidomimetic that is to be used therapeutically thereby improving at least one biological property of the peptide or peptidomimetic selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism.
- the parent peptide or peptidomimetic may have an amino acid sequence that is at least 85% identical (e.g., about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) to a sequence selected from the group consisting of SEQ ID NO: 1 (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) and SEQ ID NO: 2 (HSQGTFTSDYSKYLDSRRAQDFVQWLLNT).
- SEQ ID NO: 1 HQGTFTSDYSKYLDSRRAQDFVQWLMNT
- SEQ ID NO: 2 HQGTFTSDYSKYLDSRRAQDFVQWLLNT
- the method may further comprise amidating the c-terminus of the peptide or modifying the c-terminus of the protein with an amine.
- the peptide(s) provided by the present disclosure can be present in a form of a salt known to a person skilled in the art, such as, e.g., sodium salts, ammonium salts, calcium salts, magnesium salts, potassium salts, acetate salts, carbonate salts, citrate salts, chloride salts, sulphate salts, amino chlorhydate salts, borhydrate salts, benzensulphonate salts, phosphate salts, dihydrogenophosphate salts, succinate salts, citrate salts, tartrate salts, lactate salts, mandelate salts, methane sulfonate salts (mesylate) or p-toluene sulfonate salts (tosylate).
- a salt known to a person skilled in the art, such as, e.g., sodium salts, ammonium salts, calcium salts, magnesium salts, potassium salts, acetate salts, carbonate salts, cit
- Chemical synthesis may be performed by any method one skilled in the art would appreciate is effective at synthesizing the pro-drug peptides described herein.
- the pro-drug peptide may be polymerized by adding the required amino acids or molecules. A method is disclosed in the example section.
- compositions comprising an effective amount of one or more of the peptides as described herein, and an excipient or carrier.
- the description also provides pharmaceutical compositions comprising at least one pro-drug peptide as described herein, or a combination product as described above, further including a pharmaceutically acceptable carrier.
- compositions suitable for administration can be incorporated into pharmaceutical compositions suitable for administration.
- Such compositions typically comprise peptide and a pharmaceutically acceptable carrier.
- pharmaceutically acceptable carrier is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
- the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated.
- Supplementary active compounds e.g., additional bioactive agent
- compositions comprising formulating a pharmaceutically acceptable carrier with at least one pro-drug peptide as described herein.
- Such compositions can further include additional active agents as described above.
- the invention further includes methods for preparing a pharmaceutical composition by formulating a pharmaceutically acceptable carrier with at least one pro-drug peptide (e.g., 1, 2, 3, 4, or 5) as described herein, and one or more additional active compounds (e.g., 1, 2, 3, 4, or 5).
- a pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration.
- routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral, nasal (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration.
- Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol; antioxidants such as ascorbic acid or sodium bisulfate; chelating agents such as ethylenediamine-tetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
- the parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic.
- compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
- suitable carriers include physiological saline, bacteriostatic water, Cremophor EL (BASF; Parsippany, N.J.) or phosphate buffered saline (PBS).
- the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof.
- the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, chlorobutanol, phenol, ascorbic acid, and the like.
- isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition.
- Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a pro-drug peptide) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium, and then incorporating the required other ingredients from those enumerated above.
- the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed
- the compounds are delivered in the form of an aerosol spray from a pressurized container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
- a suitable propellant e.g., a gas such as carbon dioxide, or a nebulizer.
- Systemic administration can also be by transmucosal or transdermal means.
- penetrants appropriate to the barrier to be permeated are used in the formulation.
- penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives.
- Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.
- the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
- the compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
- suppositories e.g., with conventional suppository bases such as cocoa butter and other glycerides
- retention enemas for rectal delivery.
- the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
- a controlled release formulation including implants and microencapsulated delivery systems.
- Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
- the materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc.
- Liposomal suspensions (including liposomes having monoclonal antibodies incorporated therein or thereon) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.
- Dosage unit form refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
- the specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
- the method includes the step of administering a dosage from about 100 ng to about 5 mg of a therapeutic or pharmaceutical composition as described herein.
- the pharmaceutical composition as described herein may contain mannitol as carrier, and the composition is administered from 10 ⁇ g to 500 ⁇ g, preferably 200 ⁇ g, in a single administration.
- the dosage regimen can be reproduced from 1 to 3 times/week, every week to every four week for as long as needed with therapeutic windows and thus for several years.
- the dosage regimen is once every 4 weeks of treatment but can be repeated twice a year for several years.
- An example of administration is: one injection of 200 ⁇ g of peptide, every 4 weeks, for 12 weeks (i.e. 3 injections separated from each other by 4 weeks).
- the treatment can be prolonged by administration every 6 months.
- Preferred pharmaceutically acceptable carriers can comprise, for example, xanthan gum, locust bean gum, galactose, other saccharides, oligosaccharides and/or polysaccharides, starch, starch fragments, dextrins, British gum and mixtures thereof.
- the pharmaceutically acceptable carrier is of natural origin.
- the pharmaceutically acceptable carrier can be, or can further comprise, an inert saccharide diluent selected from a monosaccharide or disaccharide.
- Advantageous saccharide is mannitol.
- the invention relates to a pharmaceutical composition as defined above, which is in the form of a liposome, or nano particles, or in the form of a solution.
- An advantageous solution is a solution comprising from 1 to 15%, in particular about 10% of mannitol.
- the solution should be iso-osmolar.
- the invention also relates to a drug comprising a combination product as defined above, for a simultaneous, separate or sequential use.
- the present description provides methods for treating, preventing, and/or ameliorating the symptoms of hypoglycemia or a hypoglycemia-related disease or disorder.
- the method comprising administering an effective amount of the pro-drug peptides of the present disclosure or the pharmaceutical or therapeutic composition of the present disclosure to a subject in need thereof, wherein the composition is effective for treating, preventing and/or ameliorating at least one symptom of hypoglycemia or a hypoglycemia-related disease or disorder.
- the disease or disorder is insulin-induced hypoglycemia.
- the description also provides a pro-drug peptide comprising a peptide or peptidomimetic as described herein and a prodrug portion as described herein for its use as drug, in particular for the treatment of hypoglycemia or a hypoglycemia-related disease or disorder.
- pro-drug peptide or peptidomimetic of the present disclosure there are numerous ways in which to prepare the pro-drug peptide or peptidomimetic of the present disclosure.
- Fmoc/Boc protected solid phase peptide synthesis when the amine on the side chain of a lysine is functionalize, one can either switch the Fmoc/Boc protecting groups of the amines of the N-terminal lysine if it is the last amino acid, or if using an Alloc lysine, if this lysine is not the last one and a Boc on the N-terminal of the last amino acid. The Alloc at the end of the sequence would then be removed with Pd(o) and the amine functionalized.
- Peptides 3, 4, and 5 demonstrated good stability at room temperature for extended periods of time. See FIGS. 5-7, and 9 in water, PBS, and physiological serum.
- Glucagon-Based Peptides The 18 animals (rats, males, 8-week old) were housed in ventilated and enriched housing cages (310 ⁇ 125 ⁇ 127 mm 3 ) throughout the experimental phase. They were housed in groups of 3 animals during the study, on a normal 12 hours light cycle (at 08:00 pm lights off), 22 ⁇ 2° C. and 50 ⁇ 10% relative humidity. They were acclimated for 5 days with standard diet and tap water. Then, after 3 hours fasting, the animals were treated with glucagon or analogs 3, 4 and 5 (10 nM/kg) via i.v. administration. Blood glucose was measured before dosing and at 10 minutes, 20 minutes, 30 minutes, 45 minutes, 60 minutes, and 120 minutes.
- the Exemplary peptides demonstrated better ability to raise blood glucose over the course of treatment, relative to the glucagon control, as well as the inactive peptide and vehicle control.
- A1 Rink amide ( ⁇ 200 mg, loading 0.5 mmol/g) or Sieber resin ( ⁇ 160mg, loading 0.62 mmol/g) was swelled in dimethyl formaldehyde (DMF; 3 mL) for 30 minutes. Peptide synthesis was then conducted with an automated peptide synthesizer (LibertyBlue from CEM Company) using Fmoc solid phase strategy with PyBop (5 eq. relative to the resin loading) and N,N-diisopropylethylamine (DIEA; 10 eq. relative to the resin loading) as coupling reagents according to previously reported procedures (Merrifield, R. B. J. Am. Chem. Soc. 1963, 85, 2149-2154; Palasek S. A., Cox Z. J., Collins J. M. J. Pept. Sci. 2007; 13, 143-148).
- A2 Wang resin ( ⁇ 220 mg, loading 0.4 mmol/g) was swelled in DMF (3 mL) for 30 minutes. First amino-acid (5 eq.) was dissolved in dry dichloromethane (DCM; 3 mL) under inert atmosphere. N,N′-dicyclohexylcarbodiimide (DCC; 2.5 eq.) was added and the mixture was stirred 20 minutes at 0° C. before DCM concentration and DMF addition. The mixture was loaded on the swollen Wang resin with a small amount of 4-dimethylaminopyridine (DMAP). The resin was shacked for 2 hours at room temperature then filtrated and washed three times with DMF, DCM and MeOH. Then the peptide was synthesized according to procedure A1 or A2.
- Peptides 10-25 which respectfully correspond to SEQ ID NOs:1 and 14-28, were analyzed by analytical RP-HPLC on a Dionex U3000SD using a Macherey-Nagel Nucleodur C 18ec column (4 ⁇ 100 mm, 3 ⁇ m) at a flow rate of 1 mL/min with UV detection at 200 nm.
- the mobile phase was composed of 0.1% (v/v) TFA-H 2 O (Solvent A) and 0.1% (v/v) TFA-CH 3 CN (solvent B).
- LC-MS Liquid chromatography-mass spectrometry analyses were carried out on a ultra-high performance liquid chromatography (UHPLC; Agilent 1290 Infinity) coupled to an electrospray ionization time-of-flight (ESI-TOF) mass spectrometer (Agilent 6230 ESI).
- UHPLC ultra-high performance liquid chromatography
- ESI-TOF electrospray ionization time-of-flight
- Solubility Assay A solution of the compound (e.g., glucagon or analogues thereof) was prepared in a 0.01M HCl solution. Then 0.1 mL of the stock solution was diluted to 1 mL with HCl (0.01M) and the UV absorbance was measured (to 280 nm) with NanoDrop UV spectrometer (NanoDrop 1000 from Thermo Fischer Company). The pH of the remaining stock solution was adjusted to pH 7 using Na 2 HPO 4 (0.1M) and the solution was allowed to stand overnight at 4° C.
- the compound e.g., glucagon or analogues thereof
- the percent solubility of glucagon and exemplary peptides is shown in Table 2. As can be seen by the data of Table 2, the exemplary glucagon analogues have greater solubility as compared to glucagon.
- Peptide 10 was synthesized using the general procedure A2 starting from Wang resin (196 mg, 0.1 mmol) and cleaved using procedure C2. The final product 10 was purified by semi-preparative HPLC. 1.88 mg was obtained (yield 0.54%).
- HPLC: R t 5.03 min (10-100%; CH 3 CN 0.1% TFA in H 2 O 0.1% TFA, 10 min, C18); LC-MS (m/z 3482.40): 697.48 [M+5H] 5+ , 871.36 [M+4H] 4+ , 1161.82 [M+3H] 3+ .
- Peptide 11 was synthesized using the general procedure A1 starting from Sieber resin (160 mg, 0.1 mmol) and cleaved using procedure C2. The final product 11 was purified by semi-preparative HPLC. 1.59 mg was obtained (yield 0.45%).
- HPLC: R t 5.03 min (10-100%; CH 3 CN 0.1% TFA in H 2 O 0.1% TFA, 10 min, C18); LC-MS (m/z 3481.75): 697.35 [M+5H] 5+ , 871.44 [M+4H] 4+ , 1161.59 [M+3H] 3+ .
- Peptide 12 KPHSQGTFTSDYSKYLDSRRAQDFVQWLLNT-NH 2
- Peptide 12 was synthesized using the general procedure A1 starting from Sieber resin (160 mg, 0.1 mmol) and cleaved using procedure C1. The final product 12 was purified by semi-preparative HPLC. 9.26 mg was obtained (yield 2.50%).
- HPLC: R t 5.06 min (10-100%; CH 3 CN 0.1% TFA in H 2 O 0.1% TFA, 10 min, C18); LC-MS (m/z 3688.65): 615.77 [M+6H] 6+ 738.73 [M+5H] 5+ , 923.17 [M+4H] 4+ , 1230.57 [M+3H] 3+ .
- Peptide 13 KPKPHSQGTFTSDYSKYLDSRRAQDFVQWLLNT-NH 2
- Peptide 13 was synthesized using the general procedure A1 starting from Sieber resin (160 mg, 0.1 mmol) and cleaved using procedure C1. The final product 13 was purified by semi-preparative HPLC. 16.0 mg was obtained (yield 4.1%).
- HPLC: R t 5.06 min (10-100%; CH 3 CN 0.1% TFA in H 2 O 0.1% TFA, 10 min, C18); LC-MS (m/z 3914.15): 653.36 [M+6H] 6+ 783.83 [M+5H] 5+ , 979.53 [M+4H] 4+ .
- Peptide 14 KPKPKPHSQGTFTSDYSKYLDSRRAQDFVQWLLNT-NH 2
- Peptide 14 was synthesized using the general procedure A1 starting from Sieber resin (160 mg, 0.1 mmol) and cleaved using procedure C1. The final product 14 was purified by semi-preparative HPLC. 8.0 mg was obtained (yield 1.9%).
- HPLC: R t 4.91 min (10-100%; CH 3 CN 0.1% TFA in H 2 O 0.1% TFA, 10 min, C18); LC-MS (m/z 4138.20): 592.16 [M+7H] 7+ 690.7 [M+6H] 6+ 828.66 [M+5H] 5+ , 1035.60 [M+4H] 4+ .
- Peptide 15 KPHSQGTFTSDYSKYLDSRRAQDFVQWLMNT-NH 2
- Peptide 15 was synthesized using the general procedure A1 starting from Sieber resin (160 mg, 0.1 mmol) and cleaved using procedure C2. The final product 15 was purified by semi-preparative HPLC. 2.86 mg was obtained (yield 0.77%).
- HPLC: R t 5.01 min (10-100%; CH 3 CN 0.1% TFA in H 2 O 0.1% TFA, 10 min, C18); LC-MS (m/z 3706.93): 618.82 [M+6H] 6+ 742.39 [M+5H] 5+ , 927.73 [M+4H] 4+ .
- Peptide 16 KPKPHSQGTFTSDYSKYLDSRRAQDFVQWLMNT-NH 2
- Peptide 16 was synthesized using the general procedure A1 starting from Sieber resin (160 mg, 0.1 mmol) and cleaved using procedure C2. The final product 16 was purified by semi-preparative HPLC. 6.48 mg was obtained (yield 1.6%).
- HPLC: R t 4.94 min (10-100%; CH 3 CN 0.1% TFA in H 2 O 0.1% TFA, 10 min, C18); LC-MS (m/z 3932.1): 656.35 [M+6H] 6+ 787.42 [M+5H] 5+ , 984.02 [M+4H] 4+ .
- Peptide 17 KPKPKPHSQGTFTSDYSKYLDSRRAQDFVQWLMNT-NH 2
- Peptide 17 was synthesized using the general procedure A1 starting from Sieber resin (160 mg, 0.1 mmol) and cleaved using procedure C2. The final product 17 was purified by semi-preparative HPLC. 7.99 mg was obtained (yield 1.9%).
- HPLC: R t 4.93 min (10-100%; CH 3 CN 0.1% TFA in H 2 O 0.1% TFA, 10 min, C18); LC-MS (m/z 4157.22): 594.89 [M+7H] 7+ 693.87 [M+6H] 6+ 832.45 [M+5H] 5+ , 1040.31 [M+4H] 4+ .
- Peptide 18 EPHSQGTFTSDYSKYLDSRRAQDFVQWLLNT-NH 2
- Peptide 18 was synthesized using the general procedure A1 starting from Sieber resin (160 mg, 0.1 mmol) and cleaved using procedure C1. The final product 18 was purified by semi-preparative HPLC. 8.07 mg was obtained (yield 2.2%).
- HPLC: R t 5.04 min (10-100%; CH 3 CN 0.1% TFA in H 2 O 0.1% TFA, 10 min, C18); LC-MS (m/z 3689.19): 738.8 [M+5H] 5+ , 923.27 [M+4H] 4+ , 1230.73 [M+3H] 3+ .
- Peptide 19 K*PHSQGTFTSDYSKYLDSRRAQDFVQWLLNT-NH 2 ,
- K* is a lysine modified with KKKKKK
- Peptide 19 was synthesized using the general procedure A1 starting from Sieber resin (160 mg, 0.1 mmol) and cleaved using procedure C1. The final product 19 was purified by semi-preparative HPLC. 17.15 mg was obtained (yield 3.8%).
- HPLC: R t 4.62 min (10-100%; CH 3 CN 0.1% TFA in H 2 O 0.1% TFA, 10 min, C18); LC-MS (m/z 4457.46): 637.78 [M+7H] 7+ , 743.91 [M+6H] 6+ , 892.49 [M+5H] 5+ , 1115.36 [M+4H] 4+ .
- Peptide 20 K*PHSQGTFTSDYSKYLDSRRAQDFVQWLMNT-NH 2 ,
- K* is a lysine modified with KKKKKK
- Peptide 20 was synthesized using the general procedure A1 starting from Rink resin (227 mg, 0.1 mmol) and cleaved using procedure C2. The final product 20 was purified by semi-preparative HPLC. 1.9 mg was obtained (yield 0.4%).
- HPLC: R t 4.54 min (10-100%; CH 3 CN 0.1% TFA in H 2 O 0.1% TFA, 10 min, C18); LC-MS (m/z 4476.18): 560.54 [M+8H] 8+ , 640.46 [M+7H] 7+ , 747.03 [M+6H] 6+ , 896.22 [M+5H] 5+ , 1120.00 [M+4H] 4+ .
- Peptide 21 K*PHSQGTFTSDYSKYLDSRRAQDFVQWLMNT-OH,
- K* is a lysine modified with KKKKKK
- Peptide 21 was synthesized using the general procedure A2 starting from Wang resin (227 mg, 0.1 mmol) cleaved using procedure C2. The final product 21 was purified by semi-preparative HPLC. 28.11 mg was obtained (yield 6.3%).
- HPLC: R t 4.63 min (10-100%; CH 3 CN 0.1% TFA in H 2 O 0.1% TFA, 10 min, C18); LC-MS (m/z 4477.14): 640.36 [M+7H] 7+ , 746.93 [M+6H] 6+ , 896.14 [M+5H] 5+ , 1119.93 [M+4H] 4+
- Peptide 22 K*PHSQGTFTSDYSKYLDSRRAQDFVQWLLNT-NH 2 ,
- K* is a lysine modified with 8Ado8Ado
- Peptide 22 was synthesized using the general procedure A1 starting from Sieber resin (227 mg, 0.1 mmol) cleaved using procedure C1. The final product 22 was purified by semi-preparative HPLC. 1.9 mg was obtained (yield 0.4%).
- HPLC: R t 4.96 min (10-100%; CH 3 CN 0.1% TFA in H 2 O 0.1% TFA, 10 min, C18); LC-MS (m/z 3978.06): 644.01 [M+6H] 6+ , 796.63 [M+5H] 5+ , 995.57 [M+4H] 4+ , 1326.79 [M+3H] 3+ .
- Peptide 23 K*PHSQGTFTSDYSKYLDSRRAQDFVQWLLNT-NH 2 ,
- K* is a lysine modified with KKKKKK8Ado8Ado
- Peptide 23 was synthesized using the general procedure A1 starting from Sieber resin (227 mg, 0.1 mmol) and cleaved using procedure C1. The final product 23 was purified by semi-preparative HPLC. 11.99 mg was obtained (yield 2.5%).
- HPLC: R t 4.78 min (10-100%; CH 3 CN 0.1% TFA in H 2 O 0.1% TFA, 10 min, C18); LC-MS (m/z 4748.44): 594.30 [M+8H] 8+ , 679.07 [M+7H] 7+ , 792.09 [M+5H] 5+ , 950.3 [M+4H] 4+ .
- Peptide 24 K*PHSQGTFTSDYSKYLDSRRAQDFVQWLMNT-NH 2 ,
- K* is a lysine modified with KPKPKP
- Peptide 24 was synthesized using the general procedure A1 starting from Rink resin (227 mg, 0.1 mmol) and cleaved using procedure C2. The final product 24 was purified by semi-preparative HPLC. 5.0 mg was obtained (yield 1.1%).
- HPLC: R t 4.91 min (10-100%; CH 3 CN 0.1% TFA in H 2 O 0.1% TFA, 10 min, C18); LC-MS (m/z 4382.98): 627.17 [M+7H] 7+ , 731.58 [M+6H] 6+ , 877.58 [M+5H] 5+ , 1096.75 [M+4H] 4+ .
- Peptide 25 K*PHSQGTFTSDYSKYLDSRRAQDFVQWLMNT-OH,
- K* is a lysine modified with KPKPKP.
- Peptide 25 was synthesized using the general procedure A2 starting from Wang resin (216 mg, 0.1 mmol) and cleaved using procedure C2. The final product 25 was purified by semi-preparative HPLC. 7.02 mg was obtained (yield 1.6%).
- HPLC: R t 4.86 min (10-100%; CH 3 CN 0.1% TFA in H 2 O 0.1% TFA, 10 min, C18); LC-MS (m/z 4383.96): 627.14 [M+7H] 7+ , 731.50 [M+6H] 6+ , 877.60 [M+5H] 5+ , 1096.76 [M+4H] 4+ .
- the present disclosure provides a pro-drug peptide or salt thereof having improvement for at least one biological property relative to a parent peptide or peptidomimetic, wherein the biological property is selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism, the pro-drug peptide comprising the following structure: Z n -pep, wherein: pep is the parent peptide or peptidomimetic; Z is a sequence of n amino acids, wherein Z is cleaved in vivo releasing pep, and n is an integer 2 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more).
- the Z has the following structure: (Glu-Pro) m or (Lys-Pro) X , wherein X is an integer ⁇ 1 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more).
- the Z is selected from the group consisting of EP, KP, EPEP, KPKP, EPEPEP, and KPKPKP.
- At least the first Lys of Z is functionalized with a soluble compound.
- At least two Lys of Z are functionalized with the soluble compound.
- the Z comprises two amino acids, and the first amino acid is functionalized with a soluble compound.
- the soluble compound is aqueously soluble.
- the first amino acid of Z is functionalized with a soluble compound or moiety comprising: 12-aminododecanoic acid (Ado), Ado-Ado-(Lys) m , 8-amino-3,6-dioxaoctanoic acid (8Ado), 8Ado-8Ado-(Lys) m , (Lys) m , or (Pro-Lys) m , wherein m is an integer from 0-10.
- At least two Lys of Z are functionalized with a soluble compound or moiety comprising: Ado, Ado-Ado-(Lys) m , 8Ado, 8Ado-8Ado-(Lys) m , (Lys) m , or (Pro-Lys) m . wherein m is an integer from 0-10.
- the c-terminus of the peptide is amine modified or amidated.
- the parent peptide or peptidomimetic has an amino acid sequence that is at least 85% identical to a sequence selected from the group consisting of SEQ ID NO: 1 (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) and SEQ ID NO: 2 (HSQGTFTSDYSKYLDSRRAQDFVQWLLNT).
- the present disclosure provides a pharmaceutical composition
- a pharmaceutical composition comprising: an effective amount of the pro-drug of the present disclosure, and a pharmaceutically acceptable excipient or carrier.
- the present disclosure provides a method of treating or preventing hypoglycemia or a hypoglycemia related disorder or disease, the method comprising: administering an effective amount of the pro-drug peptide of the present disclosure or the pharmaceutical composition of the present disclosure, wherein the pro-drug peptide is effective at treating or preventing hypoglycemia or the hypoglycemia related disorder or disease.
- the present disclosure provides a method of preparing a pro-drug peptide or salt thereof having improvement for at least one biological property relative to a parent peptide or peptidomimetic, wherein the biological property is selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism.
- the method comprising: adding a pro-drug portion to the parent peptide or peptidomimetic, wherein the pro-drug portion comprises ⁇ 2 amino acids that are cleaved in vivo releasing the peptide or peptidomimetic.
- the pro-drug portion has the following structure: (Glu-Pro) m or (Lys-Pro) X , wherein X is ⁇ 1 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more).
- the pro-drug portion is selected from the group consisting of EP, KP, EPEP, KPKP, EPEPEP, and KPKPKP.
- At least the first Lys of the pro-drug portion is functionalized with a soluble compound or moiety.
- At least two Lys of the pro-drug portion are functionalized with the soluble compound or moiety.
- the pro-drug portion comprises two amino acids, and the first amino acid is functionalized with the soluble compound or moiety.
- the soluble compound is hydrophilic (i.e., soluble in aqueous solution).
- the first amino acid of the pro-drug portion is functionalized with a soluble compound or moiety comprising: 12-aminododecanoic acid (Ado), Ado-Ado-(Lys) m , 8-amino-3,6-dioxaoctanoic acid (8Ado), 8Ado-8Ado-(Lys) m , (Lys) m , or (Pro-Lys) m . wherein m is an integer from 0-10.
- At least two Lys of the pro-drug portion is functionalized with a soluble compound or moiety comprising: Ado, Ado-Ado-(Lys) m , 8Ado, 8Ado-8Ado-(Lys) m , (Lys) m , or (Pro-Lys) m , wherein m is an integer from 0-10.
- the c-terminus of the peptide is amine modified or amidated.
- the parent peptide or peptidomimetic has an amino acid sequence that is at least 85% identical to a sequence selected from the group consisting of SEQ ID NO: 1 (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) and SEQ ID NO: 2 (HSQGTFTSDYSKYLDSRRAQDFVQWLLNT).
- the peptide or peptidomimetic includes or is a peptide selected from SEQ ID NO: 3-10 and 11-25.
- the peptide or peptidomimetic includes or is elected from 2-9 and 11-25.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Immunology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
The present disclosure relates to a pro-drug peptide, or a salt thereof, having improvement for at least one biological property relative to a parent peptide or peptidomimetic, wherein the biological property is selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism. The pro-drug peptide comprising the following structure: Z-pep, wherein: pep is the parent peptide or peptidomimetic; Z is a sequence of n amino acids, Z is cleaved in vivo releasing pep; n≥2 amino acids. The present disclosure also relates to methods of making and using the pro-drug peptide of the present disclosure. For example, the present disclosure describes a pro-drug peptide that may be used to prevent, treat, or ameliorate at least one symptom of hypoglycemia or a hypoglycemia-related disease or disorder.
Description
- The present disclosure is a Continuation of U.S. patent application Ser. No. 16/023,901, filed on 29 Jun. 2018, which claims priority to U.S. Provisional Patent Application No. 62/526,678, filed 29 Jun. 2017, entitled “PRO-DRUG PEPTIDE WITH IMPROVED PHARMACEUTICAL PROPERTIES”; all of which are hereby incorporated by reference in their entirety for all purposes.
- An electronic version of the Sequence Listing file name: URZ0008US2C_Sequence_Listing_26JUN2018_ST25.txt, size: 13.0 KB containing SEQ ID NOs: 1-31 is filed herewith and is hereby incorporated by reference in its entirety.
- The present disclosure relates to pro-drug peptides, making the same, and using the same for treating diseases. In particular, the present disclosure relates to a pro-drug peptide that includes a parent peptide or peptidomimetic and a pro-drug portion that includes at least two amino acids that are cleaved in vivo, releasing the parent peptide or peptidomimetic.
- Pro-drugs are compounds that are metabolized by the subject after administration to form a pharmaceutically active compound or drug. The general object of a prodrug is to mask undesirable properties. For example, irritation or pain after local administration, chemical instability, low target selectively, low solubility in water or lipid membranes, toxicity, pre-systemic metabolism, among others. As such, pro-drug modifications are designed to optimize, inter alia, adsorption, distribution, metabolism, excretion, and/or unwanted toxicity of a parent compound or drug. As a result, prodrugs are used, inter alia, to optimize therapeutic index, decrease toxicity, improve adsorption, decrease pre-systemic metabolism, improve solubility and improve chemical stability.
- Pro-drugs can be classified into two general categories:
Type 1 and Type II pro-drugs. Type I pro-drugs (e.g., anti-viral nucleoside analogs) are pro-drugs that are bioactivated intracellularly with Type IA being metabolized at the cellular targets of their therapeutic action and Type IB being converted by metabolic tissues (e.g., the liver). Type II pro-drugs (e.g., salicin) are bioactivated extracellularly with Type IIA being converted in the gastrointestinal fluid, Type IIB being converted in extracellular fluid compartments (e.g., circulatory system), and Type IIC being converted near or inside therapeutic targets/cells. - Glucagon is a 29 amino acid peptide hormone that is produced by pancreatic alpha-cells in response to low blood glucose levels, thereby stimulating glycogenolysis (i.e., the breakdown of glycogen [n] to glucose-6-phosphate and glycogen [n−1]) and gluconeogenesis (i.e., the synthesis of glucose from non-carbohydrate carbon substrates), and inhibiting glycogenesis (i.e., the synthesis of glycogen from sugar). As a result, there is a rapid increase in blood glucose.
- Because of insulins low therapeutic index, insulin-dependent diabetes is a well-known risk factor for severe hypoglycaemia, where blood glucose levels can fall below 50 mg/dl. The standard treatment for hypoglycaemia (such as severe insulin-induced hypoglycaemia) is acute subcutaneous administration of glucagon. Because of glucagon's poor chemical stability, however, glucagon is supplied in a lyophilized powder that is prepared immediately prior to administration. Furthermore, because of glucagon's poor aqueous solubility at physiological pH, the solution for administration is prepared with dilute aqueous hydrochloric acid. Also because of glycogen's chemical instability, the dilute hydrochloric acid prepared glucagon must be used immediately.
- Thus, there exists a need for a method of making therapeutics with enhanced chemical stability, aqueous solubility, therapeutic index, and adsorption, as well as decreased toxicity and pre-systemic metabolism. For example, there exists a need for a pro-drug of glucagon that has enhanced chemical stability and aqueous solubility at physiological pH, relative to the parent peptide glucagon, for use as a therapeutic intervention, e.g., hypoglycaemia.
- The present description provides therapeutic compositions and methods of making and using the same that are based on the surprising and unexpected discovery that chemically modified peptides as described herein have improvement for at least one biological property (such as, a biological property whose improvement enhances its therapeutic effect) relative to a parent peptide or peptidomimetic (i.e., the unmodified peptide). The modified peptides or peptidomimetic as described herein include a pro-drug portion that is cleaved in vivo, after administration, to release the parent peptide or peptidomimetic. The described peptides and compositions comprising effective amounts of the same are effective for treating, preventing and/or ameliorating the symptoms of diseases and disorders that are treated, prevented, or ameliorated by the release of the parent peptide or peptidomimetic (for example, the release of glucagon or an analog thereof to treat a hypoclycemia related disease or disorder). Accordingly, in certain additional aspects, the disclosure provides methods of making and using the described peptides and compositions comprising the same for the treatment, prevention and/or amelioration of the symptoms a hypoglycemia relates disease or disorder.
- Thus, in an aspect, the present disclosure provides a pro-drug peptide or a salt thereof (e.g., a pharmaceutical salt thereof) having improvement for at least one biological property relative to a parent peptide or peptidomimetic, wherein the biological property is selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism, the pro-drug peptide comprising the following structure:
-
Zn-pep, - wherein: pep is the parent peptide or peptidomimetic; Z is a pro-drug portion, e.g., an amino acid sequence of n amino acids, wherein Z is cleaved in vivo releasing pep; and n is an integer ≥2 amino acids.
- In some embodiments, the Z has the following structure: (Glu-Pro)m or (Lys-Pro)X, wherein X is an integer ≥1.
- In certain embodiments, at least the first Lys of Z is functionalized with a soluble compound or moiety.
- In particular embodiments, at least two Lys of Z are functionalized with a soluble compound or moiety.
- In other embodiments, the Z comprises two amino acids, and the first amino acid is functionalized with a soluble compound or moiety.
- In additional embodiments, the soluble compound is hydrophilic or soluble in aqueous solution.
- In further embodiments, the Z is selected from the group consisting of EP, KP, EPEP, KPKP, EPEPEP, and KPKPKP.
- In certain other embodiments, the first amino acid of Z is functionalized with a soluble compound or moiety comprising: 12-aminododecanoic acid (Ado), Ado-Ado-(Lys)m, 8-amino-3,6-dioxaoctanoic acid (8Ado), 8Ado-8Ado-(Lys)m, (Lys)m, or (Pro-Lys)m, wherein m is an integer from 0-10.
- In some embodiments, at least two Lys of Z are functionalized with a soluble compound or moiety comprising: Ado, Ado-Ado-(Lys)m, 8Ado, 8Ado-8Ado-(Lys)m, (Lys)m, or (Pro-Lys)m. wherein m is an integer from 0-10.
- In particular embodiments, the c-terminus of the peptide is amine modified or amidated.
- In another embodiment, the parent peptide or peptidomimetic has an amino acid sequence that is at least 85% identical to a sequence selected from the group consisting of SEQ ID NO: 1 (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) and SEQ ID NO: 2 (HSQGTFTSDYSKYLDSRRAQDFVQWLLNT).
- According to another aspect, a pharmaceutical composition is provided that comprises an effective amount of at least one pro-drug of the present disclosure, and a pharmaceutically acceptable excipient or carrier. In certain additional aspects, the description provides therapeutic compositions comprising an effective amount of at least one pro-drug peptide of the present disclosure, and an effective amount of at least one additional bioactive agent. In certain embodiments, the composition further comprises an excipient or carrier as described herein.
- According to yet another aspect, the present disclosure provides a method of treating or preventing hypoglycemia or a hypoglycemia related disorder or disease. The method comprises: administering an effective amount of the pro-drug peptide of the present disclosure or the pharmaceutical composition of the present disclosure, wherein the pro-drug peptide is effective at treating or preventing hypoglycemia or the hypoglycemia related disorder or disease.
- According to a further aspect, the present disclosure provides a method of preparing a pro-drug peptide or salt thereof (e.g., a pharmaceutical salt thereof) having improved biological property or properties (e.g., at least one biological property selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism) relative to a parent peptide or peptidomimetic. The method comprises: adding a pro-drug portion to the parent peptide or peptidomimetic (e.g., synthesizing the pro-drug portion and the peptide or peptidomimetic as a contiguous sequence by any method known or that becomes known to those skilled in the art), wherein the pro-drug portion comprises ≥2 amino acids that are cleaved in vivo releasing the peptide or peptidomimetic.
- In particular embodiments, the pro-drug portion is located at the amino-terminus of the parent peptide or peptidomimetic. In other embodiments, the pro-drug portion is located at the carboxyl-terminus of the parent peptide or peptidomimetic.
- In some embodiments, the pro-drug portion has the following structure: (Glu-Pro)m or (Lys-Pro)X, wherein X is an integer ≥1.
- In certain embodiments, at least the first Lys of the pro-drug portion is functionalized with a soluble compound.
- In additional embodiments, at least two Lys of the pro-drug portion are functionalized with a soluble compound.
- In particular embodiments, the pro-drug portion comprises two amino acids, and the first amino acid is functionalized with a soluble compound.
- In other embodiment, the soluble compound is aqueously soluble.
- In an embodiment, the pro-drug portion is selected from the group consisting of EP, KP, EPEP, KPKP, EPEPEP, and KPKPKP.
- In yet other embodiments, the first amino acid of the pro-drug portion is functionalized with a soluble compound or moiety comprising: 12-aminododecanoic acid (Ado), Ado-Ado-(Lys)m, 8-amino-3,6-dioxaoctanoic acid (8Ado), 8Ado-8Ado-(Lys)m, (Lys)m, or (Pro-Lys)m. wherein m is an integer from 0-10.
- In some embodiments, at least two Lys of the pro-drug portion is functionalized with a soluble compound or moiety comprising: Ado, Ado-Ado-(Lys)m, 8Ado, 8Ado-8Ado-(Lys)m, (Lys)m, or (Pro-Lys)m, wherein m is an integer from 0-10.
- In yet other embodiments the parent peptide or peptidomimetic has an amino acid sequence that is at least 85% identical to a sequence selected from the group consisting of SEQ ID NO: 1 (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) and SEQ ID NO: 2 (HSQGTFTSDYSKYLDSRRAQDFVQWLLNT).
- In other embodiments, the method further comprises amidating the c-terminus of the peptide.
- In another embodiment, the method further comprises modifying the c-terminus of the protein with an amine.
- The preceding general areas of utility are given by way of example only and are not intended to be limiting on the scope of the present disclosure and appended claims. Additional objects and advantages associated with the compositions, methods, and processes of the present invention will be appreciated by one of ordinary skill in the art in light of the instant claims, description, and examples. For example, the various aspects and embodiments of the invention may be utilized in numerous combinations, all of which are expressly contemplated by the present description. These additional advantages objects and embodiments are expressly included within the scope of the present invention. The publications and other materials used herein to illuminate the background of the invention, and in particular cases, to provide additional details respecting the practice, are incorporated by reference.
- The accompanying drawings, which are incorporated into and form a part of the specification, illustrate several embodiments of the present invention and, together with the description, serve to explain the principles of the invention. The drawings are only for the purpose of illustrating an embodiment of the invention and are not to be construed as limiting the invention.
-
FIG. 1 . Illustrates and aligns peptides 1-9, which includes a parent peptide and several exemplary pro-drugs including the same. -
FIG. 2 . Illustrates an exemplary functionalization of a Lys with Lys-Lys-Lys-Lys-Lys-Lys, wherein when the Lys is at the N-terminus one skilled in the art appreciates that a hydrogen is bound to the nitrogen on the left side of the chemical structure. -
FIG. 3 . Illustrates an exemplary functionalization of a Lys with 8Ado-8Ado, wherein when K* is the N-terminus one skilled in the art appreciates that a hydrogen is bound to the nitrogen on the left side of the chemical structure. -
FIG. 4 . Illustrates an exemplary functionalization of a Lys with Ado-Ado, wherein when K* is the N-terminus one skilled in the art appreciates that a hydrogen is bound to the nitrogen on the left side of the chemical structure. -
FIG. 5 . Stability of peptide 3 (1 mg/mL) in PBS (phosphate buffered saline) at room temperature over 10 days. -
FIG. 6 . Stability of peptide 4 (1 mg/mL) in water at room temperature over 46 days. -
FIG. 7 . Stability of peptide 4 (1 mg/mL) in physiological serum at room temperature over 18 days. -
FIG. 8 . Stability of peptide 5 (1 mg/mL) in physiological serum at 4° C. over 7 days. -
FIG. 9 . Stability of peptide 5 (1 mg/mL) in physiological serum at room temperature over 18 days. -
FIG. 10 . Blood glucose measurement (mg/dl) 30 min before dosing then at t=10 minutes, 20 minutes, 30 minutes, 45 minutes, 60 minutes, and 120 minutes after injection, * p<0.05; ** p<0.01: two way anova with Bonferroni posttests. -
FIG. 11A andFIG. 11B . (A) Illustrates and aligns of peptides 10-25, which includes the parent peptide and several exemplary pro-drugs including the same. (B) Illustrates the chemical structure of the modified lysines illustrated inFIG. 11A , wherein when K* is the N-terminus one skilled in the art appreciates that a hydrogen is bound to the nitrogen on the left side of the chemical structure. -
FIG. 12 . Blood glucose measurement (mg/dl) 30 minutes before dosing Wistar rats with vehicle andcompound -
FIG. 13 . Blood glucose measurement (mg/dl) before and after dosing Wistar rats with vehicle andcompound -
FIG. 14A andFIG. 14B . (A) High-performance liquid chromatography (HPLC) profile of peptide 10 (10-100%; CH3CN 0.1% trifluoroacetic acid (TFA) in H2O 0.1% TFA, 10 min, C18). (B) liquid chromatography-mass spectrometry (LC-MS) spectrum ofpeptide 10. -
FIG. 15A andFIG. 15B . (A) HPLC profile of peptide 11 (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 11. -
FIG. 16A andFIG. 16B . (A) HPLC profile of peptide 12 (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 12. -
FIG. 17A andFIG. 17B . (A) HPLC profile of peptide 13 (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 13. -
FIG. 18A andFIG. 18B . (A) HPLC profile of peptide 14 (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum ofpeptide 14. -
FIG. 19A andFIG. 19B . (A) HPLC profile of peptide 15 (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum ofpeptide 15. -
FIG. 20A andFIG. 20B . (A) HPLC profile of peptide 16 (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 16. -
FIG. 21A andFIG. 21B . (A) HPLC profile of peptide 17 (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 17. -
FIG. 22A andFIG. 22B . (A) HPLC profile of peptide 18 (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum ofpeptide 18. -
FIG. 23A andFIG. 23B . (A) HPLC profile of peptide 19 (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum ofpeptide 19. -
FIG. 24A andFIG. 24B . (A) HPLC profile of peptide 20 (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum ofpeptide 20. -
FIG. 25A andFIG. 25B . (A) HPLC profile of peptide 21 (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 21. -
FIG. 26A andFIG. 26B . (A) HPLC profile of peptide 22 (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 22. -
FIG. 27A andFIG. 27B . (A) HPLC profile of peptide 23 (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 23. -
FIG. 28A andFIG. 28B . (A) HPLC profile of peptide 24 (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum of peptide 24. -
FIG. 29A andFIG. 29B . (A) HPLC profile of peptide 25 (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18). (B) LC-MS spectrum ofpeptide 25. - The following is a detailed description of the invention provided to aid those skilled in the art in practicing the present invention. Those of ordinary skill in the art may make modifications and variations in the embodiments described herein without departing from the spirit or scope of the present invention. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, the preferred methods and materials are now described. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the present disclosure is for describing particular embodiments only and is not intended to be limiting of the invention. All publications, patent applications, patents, figures and other references mentioned herein are expressly incorporated by reference in their entirety.
- Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the present disclosure. The upper and lower limits of these smaller ranges which may independently be included in the smaller ranges is also encompassed within the present disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either both of those included limits are also included in the present disclosure.
- As used herein, the following terms may have meanings ascribed to them below, unless specified otherwise. However, it should be understood that other meanings that are known or understood by those having ordinary skill in the art to which the present disclosure belongs are also possible, and within the scope of the present disclosure.
- It must be noted that as used herein and in the appended claims, the singular forms “a”, “and”, and “the” include plural references (i.e., refer to one or to more than one or at least one) to the grammatical object of the article. By way of example, “an element” means one element or more than one element.
- The term “about” as it is used herein, in association with numeric values or ranges, reflects the fact that there is a certain level of variation that is recognized and tolerated in the art due to practical and/or theoretical limitations. For example, minor variation is tolerated due to inherent variances in the manner in which certain devices operate and/or measurements are taken. In accordance with the above, the phrase “about” is normally used to encompass values within the standard deviation or standard error.
- The phrase “and/or,” as used herein in the specification and in the claims, should be understood to mean “either or both” of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Multiple elements listed with “and/or” should be construed in the same fashion, i.e., “one or more” of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified by the “and/or” clause, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to “A and/or B”, when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.
- As used herein in the specification and in the claims, “or” should be understood to have the same meaning as “and/or”, as defined above. For example, when separating items in a list, “or” or “and/or” shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as “only one of” or “exactly one of,” or, when used in the claims, “consisting of,” will refer to the inclusion of exactly one element of a number or list of elements. In general, the term “or” as used herein shall only be interpreted as indicating exclusive alternatives (i.e., “one or the other but not both”) when preceded by terms of exclusivity, such as “either,” “one of,” “only one of,” or “exactly one of.”
- In the claims, as well as in the specification above, all transitional phrases such as “comprising,” “including,” “carrying,” “having,” “containing,” “involving,” “holding,” “composed of,” and the like are to be understood to be open-ended, i.e., to mean including but not limited to. Only the transitional phrases “consisting of” and “consisting essentially of” shall be closed or semi-closed transitional phrases, respectively, as set forth in the United States Patent Office Manual of Patent Examining Procedures, Section 2111.03.
- As used herein in the specification and in the claims, the phrase “at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from anyone or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements. This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase “at least one” refers, whether related or unrelated to those elements specifically identified. Thus, as a nonlimiting example, “at least one of A and B” (or, equivalently, “at least one of A or B,” or, equivalently “at least one of A and/or B”) can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.
- It should also be understood that, in certain methods described herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited unless the context indicates otherwise.
- The terms “co-administration” and “co-administering” or “combination therapy” refer to both concurrent administration (administration of two or more therapeutic agents at the same time) and time varied administration (administration of one or more therapeutic agents at a time different from that of the administration of an additional therapeutic agent or agents), as long as the therapeutic agents are present in the patient to some extent, preferably at effective amounts, at the same time. In certain preferred aspects, one or more of the present compounds described herein, are coadministered in combination with at least one additional bioactive agent, e.g. an agent that stimulates glycogenolysis, stimulates gluconeogenesis, and/or inhibiting glycogenesis. In particularly preferred aspects, the co-administration of compounds results in synergistic activity and/or therapy, including anti-hypoclycemic activity.
- The term “compound”, “peptide”, and “peptidomimetic”, as used herein, unless otherwise indicated, refers to any specific chemical compound disclosed herein and includes tautomers, regioisomers, geometric isomers, and where applicable, stereoisomers, including optical isomers (enantiomers) and other steroisomers (diastereomers) thereof, as well as pharmaceutically acceptable salts and derivatives (including prodrug forms) thereof where applicable, in context. Within its use in context, the term compound generally refers to a single compound, but also may include other compounds such as stereoisomers, regioisomers and/or optical isomers (including racemic mixtures) as well as specific enantiomers or enantiomerically enriched mixtures of disclosed compounds. The term also refers, in context to prodrug forms of compounds which have been modified to facilitate the administration and delivery of compounds to a site of activity. It is noted that in describing the present compounds, numerous substituents and variables associated with same, among others, are described. It is understood by those of ordinary skill that molecules which are described herein are stable compounds as generally described hereunder.
- The term “derivatives” can mean, but is in no way limited to, chemical compositions, for example, nucleic acids, nucleotides, polypeptides or amino acids, formed from the native compounds either directly, by modification, or by partial substitution. The term “analogs” can mean, but is in no way limited to, chemical compositions, for example, nucleic acids, nucleotides, polypeptides or amino acids that have a structure similar to, but not identical to, the native compound.
- The term “effective amount/dose,” “pharmaceutically effective amount/dose,” “pharmaceutically effective amount/dose” or “therapeutically effective amount/dose” can mean, but is in no way limited to, that amount/dose of the active pharmaceutical ingredient sufficient to prevent, inhibit the occurrence, ameliorate, delay or treat (alleviate a symptom to some extent, preferably all) at least one symptom of a condition, disorder or disease state. The effective amount depends on the type of disease, the composition used, the route of administration, the type of mammal being treated, the physical characteristics of the specific mammal under consideration, concurrent medication, and other factors which those skilled in the medical arts will recognize. Generally, an amount between 0.1 mg/kg and 1000 mg/kg body weight/day of active ingredients is administered dependent upon potency of the agent. Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Compounds that exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects. The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosages for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the present disclosure, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.
- The term “pharmacological composition,” “therapeutic composition,” “therapeutic formulation” or “pharmaceutically acceptable formulation” can mean, but is in no way limited to, a composition or formulation that allows for the effective distribution of an agent provided by the present disclosure, which is in a form suitable for administration to the physical location most suitable for their desired activity, e.g., systemic administration.
- The term “pharmaceutically acceptable” or “pharmacologically acceptable” can mean, but is in no way limited to, entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, or a human, as appropriate.
- The term “pharmaceutically acceptable carrier” or “pharmacologically acceptable carrier” can mean, but is in no way limited to, any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, ringer's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
- The term “systemic administration” refers to a route of administration that is, e.g., enteral or parenteral, and results in the systemic distribution of an agent leading to systemic absorption or accumulation of drugs in the blood stream followed by distribution throughout the entire body. Suitable forms, in part, depend upon the use or the route of entry, for example oral, transdermal, or by injection. Such forms should not prevent the composition or formulation from reaching a target cell (i.e., a cell to which the negatively charged polymer is desired to be delivered to). For example, pharmacological compositions injected into the blood stream should be soluble. Other factors are known in the art, and include considerations such as toxicity and forms which prevent the composition or formulation from exerting its effect. Administration routes which lead to systemic absorption include, without limitations: intravenous, subcutaneous, intraperitoneal, inhalation, oral, intrapulmonary and intramuscular. The rate of entry of a drug into the circulation has been shown to be a function of molecular weight or size. The use of a liposome or other drug carrier comprising the compounds of the instant invention can potentially localize the drug, for example, in certain tissue types, such as the tissues of the reticular endothelial system (RES). A liposome formulation which can facilitate the association of drug with the surface of cells, such as, lymphocytes and macrophages is also useful.
- The term “local administration” refers to a route of administration in which the agent is delivered to a site that is apposite or proximal, e.g., within about 10 cm, to the site of the lesion or disease.
- The term “conservative mutations” refers to the substitution, deletion or addition of nucleic acids that alter, add or delete a single amino acid or a small number of amino acids in a coding sequence where the nucleic acid alterations result in the substitution of a chemically similar amino acid. Amino acids that may serve as conservative substitutions for each other include the following: Basic: Arginine (R), Lysine (K), Histidine (H); Acidic: Aspartic acid (D), Glutamic acid (E), Asparagine (N), Glutamine (Q); hydrophilic: Glycine (G), Alanine (A), Valine (V), Leucine (L), Isoleucine (I); Hydrophobic: Phenylalanine (F), Tyrosine (Y), Tryptophan (W); Sulfur-containing: Methionine (M), Cysteine (C). In addition, sequences that differ by conservative variations are generally homologous.
- By “homology” or “identity” is meant the nucleotide sequence of two or more nucleic acid molecules or two or more nucleic acid or amino acid sequences is partially or completely identical. In certain embodiments the homologous nucleic acid or amino acid sequence has 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% sequence similarity or identity to the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2, respectively.
- “Homologs” can be naturally occurring, or created by artificial synthesis of one or more nucleic acids (or amino acids resulting therefrom) having related sequences, or by modification of one or more nucleic acid (or amino acids that result therefrom) to produce related nucleic acids. Nucleic acids (and thus the resultant amino acid sequence) are homologous when they are derived, naturally or artificially, from a common ancestor sequence (e.g., orthologs or paralogs). If the homology between two nucleic acids is not expressly described, homology can be inferred by a nucleic acid comparison between two or more sequences (including the amino acid sequences). If the sequences demonstrate some degree of sequence similarity, for example, greater than about 30% at the primary amino acid structure level, it is concluded that they share a common ancestor. For purposes of the present disclosure, nucleic acid sequences are homologous if the sequences are sufficiently similar to allow recombination and/or hybridization under low stringency conditions. In addition, polypeptides are regarded as homologous if their nucleic acid sequences are sufficiently similar to allow recombination or hybridization under low stringency conditions, and optionally they demonstrate similar activity as the parent peptide, and optionally they can be recognized by (i.e., cross-react with) an antibody specific for an epitope contained within the amino acid sequence of the patent peptide, e.g., at least one of SEQ ID NO: 1 or SEQ ID NO: 2.
- The term “cell” can mean, but is in no way limited to, it's usual biological sense, and does not refer to an entire multicellular organism. The cell can, for example, be in vivo, in vitro or ex vivo, e.g., in cell culture, or present in a multicellular organism, including, e.g., birds, plants and mammals such as humans, cows, sheep, apes, monkeys, swine, dogs, and cats. The cell can be prokaryotic (e.g., bacterial cell) or eukaryotic (e.g., mammalian or plant cell).
- The term “host cell” can mean, but is in no way limited to, a cell that might be used to carry a heterologous nucleic acid, or expresses a peptide or protein encoded by a heterologous nucleic acid. A host cell can contain genes that are not found within the native (non-recombinant) form of the cell, genes found in the native form of the cell where the genes are modified and re-introduced into the cell by artificial means, or a nucleic acid endogenous to the cell that has been artificially modified without removing the nucleic acid from the cell. A host cell may be eukaryotic or prokaryotic. General growth conditions necessary for the culture of bacteria can be found in texts such as BERGEY'S MANUAL OF SYSTEMATIC BACTERIOLOGY, Vol. 1, N. R. Krieg, ed., Williams and Wilkins, Baltimore/London (1984). A “host cell” can also be one in which the endogenous genes or promoters or both have been modified to produce one or more of the polypeptide components of the complex of the invention.
- The term “patient” or “subject” is used throughout the specification to describe an animal, preferably a human or a domesticated animal, to whom treatment, including prophylactic treatment, with the compositions according to the present invention is provided. For treatment of those infections, conditions or disease states which are specific for a specific animal such as a human patient, the term patient refers to that specific animal, including a domesticated animal such as a dog or cat or a farm animal such as a horse, cow, sheep, etc. In general, in the present invention, the term patient refers to a human patient unless otherwise stated or implied from the context of the use of the term.
- The term “therapeutically effective amount or dose” includes a dose of a drug that is capable of achieving a therapeutic effect in a subject in need thereof. For example, a therapeutically effective amount of a drug can be the amount that is capable of preventing or relieving one or more symptoms associated with a disease or disorder, e.g., tissue injury or muscle-related disease or disorder. The exact amount can be ascertainable by one skilled in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins).
- A kit is any manufacture (e.g. a package or container) comprising at least one pro-drug peptide of the present disclosure or pharmaceutical composition of the present disclosure. The manufacture may be promoted, distributed, or sold as a unit for performing the methods of the present disclosure. In addition, the kits of the present disclosure may preferably contain instructions which describe a suitable administration method. Such kits can be conveniently used, e.g., in clinical settings, to treat or ameliorate patients exhibiting symptoms of disease or disorder (such as, a hypoglycemia or hypoglycemia relates disease or disorder).
- All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
- The following references, the entire disclosures of which are incorporated herein by reference, provide one of skill with a general definition of many of the terms used in this invention: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, the Harper Collins Dictionary of Biology (1991).
- The present description provides therapeutic compositions and methods of using the same that are based on the surprising and unexpected discovery that the chemically modified peptides or peptidomimetics as described herein have improved one or more biological properties. In particular, the pro-drug peptide of the present disclosure includes improvement in at least one biological property (such as, a biological property whose improvement enhances its therapeutic effect) relative to a parent peptide or peptidomimetic (i.e., the unmodified peptide). The modified peptides (i.e., the pro-drug peptides) of the present disclosure include a pro-drug portion that is cleaved in vivo, after administration, to release the parent peptide or peptidomimetic.
- Without being limited to any particular theory, it is hypothesized that that the parent peptide or peptidomimetic is released from the pro-drug form via dipeptidyl peptidase-4 (DPP4), which also known as adenosine
deaminase complexing protein 2 or CD26 (cluster of differentiation 26). That is, It is believed that DDP4, which is a serine exopeptidase expressed on the surface of most cell types and that cleaves X-proline dipeptides from the N-terminus of polypeptides, cleaves the pro-drug portion in vivo to release the patent peptide or peptidomimetic. However, it is possible that other enzyme or enzymes may be involved in or facilitate, alone or in combination with DDP4, in the release of the parent peptide or peptidomimetic from the pro-drug form. - Pharmacological peptides or peptidomimetics display a number of advantageous properties that makes them excellent therapeutics, notably for autoimmune diseases. In addition to their synthesis and production that can be highly optimized, and in some cases remarkably simple in comparison to some biologics, and automatable, peptides or peptidomimetics selected as active components of pharmaceutical compositions are characterized by their stability and robustness, easy handling, the relatively low doses that have to be administrated to patients and their cost, which remains reasonable with regard to most biologics. Short peptides are not immunogenic per se, which is another considerable advantage for treating patients with chronic autoimmune diseases (Schall and Muller, 2014).
- The present description provides therapeutic compositions and methods of using the same that are based on the surprising and unexpected discovery that chemically modified peptides or peptidomimetics as described herein create pro-drugs with improved biological properties that enhance the therapeutic effect of the parent peptide or peptidomimetic. In an aspect, the present disclosure provides a pro-drug peptide or a salt thereof (e.g., a pharmaceutical salt thereof) having improvement for at least one biological property relative to a parent peptide or peptidomimetic, wherein the biological property is selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism, the pro-drug peptide comprising the following structure:
-
Zn-pep, - wherein: pep is the parent peptide or peptidomimetic; Z is a pro-drug portion, e.g., an amino acid sequence of n amino acids, wherein Z (pro-drug portion) is cleaved in vivo releasing pep; and n is an integer of ≥2 amino acids (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more).
- The pro-drug portion (Z) can have the following structure: (Glu-Pro)m or (Lys-Pro)X, wherein X is an integer ≥1 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more). For Example, Z can be Glu-Pro, Lys-Pro, Glu-Pro-Glu-Pro (SEQ ID NO: 30), Lys-Pro-Lys-Pro (SEQ ID NO: 11), Glu-Pro-Glu-Pro-Glu-Pro (SEQ ID NO: 31), and Lys-Pro-Lys-Pro-Lys-Pro (SEQ ID NO: 12). In other embodiments, the Z comprises two amino acids, and the first amino acid is functionalized with a soluble compound as described herein. In any embodiment described herein, at least the first amino acid (e.g., Lys) of the pro-drug portion (e.g., the first amino acid, the third amino acid, the fifth amino acid, the seventh amino acid, or a combination thereof, such as the first and third amino acid (e.g., first and second Lys); the first and fifth amino acid (e.g., first and third Lys); the first, third, and fifth amino acid (e.g., first, second, and third Lys; etc.) can be functionalized with a soluble compound. In particular embodiments, at least one (e.g., at least two, at least three, or at least four) Lys of Z are functionalized with a soluble compound as described herein.
- The soluble compound may be aqueously soluble. For example, the pro-drug portion may be functionalized with a soluble compound comprising: 12-aminododecanoic acid (Ado), Ado-Ado-(Lys)m, 8-amino-3,6-dioxaoctanoic acid (8Ado), 8Ado-8Ado-(Lys)m, (Lys)m (e.g., [Lys]6; SEQ ID NO: 13), or (Pro-Lys)m (e.g., [Pro-Lys]3, SEQ ID NO: 29), wherein m is an integer from 0-10. In some embodiments, at least two Lys of Z (e.g., two, three, or four) are functionalized with a soluble compound, which may comprise: Ado, Ado-Ado-(Lys)m, 8Ado, 8Ado-8Ado-(Lys)m, (Lys)m (e.g., [Lys]6; SEQ ID NO: 13), or (Pro-Lys)m (e.g., [Pro-Lys]3, SEQ ID NO: 29), wherein m is an integer from 0-10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10).
- The peptide may be amine modified at the c-terminus or the c-terminus of the peptide may be amidated.
- The parent peptide or peptidomimetic can be any peptide or peptidomimetic one wishes to improve at least one biological property that enhances the therapeutic effect of the peptide or peptidomimetic. For example, the parent peptide or peptidomimetic may have an amino acid sequence that is at least 60% identical (e.g., at least 65%, 70%, 75%, 80%, 85%, 90%, 92.5%, 95%, 97.5%, 98%, 99%, or 100% identical) to glucagon. In a particular embodiments, the parent peptide or peptidomimetic has an amino acid sequence that is at least 60% identical (e.g., at least 65%, 70%, 75%, 80%, 85%, 90%, 92.5%, 95%, 97.5%, 98%, 99%, or 100% identical) to a sequence selected from the group consisting of SEQ ID NO: 1 (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) and SEQ ID NO: 2 (HSQGTFTSDYSKYLDSRRAQDFVQWLLNT).
- According to another aspect, a pharmaceutical composition is provided that comprises at least one pro-drug peptide of the present disclosure, and a pharmaceutically acceptable excipient or carrier. In certain additional aspects, the description provides therapeutic compositions comprising at least one pro-drug peptide of the present disclosure, and at least one additional bioactive agent. For example, when the parent peptide is glucagon or a peptidomimetic thereof, the additional bioactive agent can be any agent that stimulates glycogenolysis, stimulates gluconeogenesis, and/or inhibiting glycogenesis. In certain embodiments, the composition further comprises an excipient (e.g., a pharmaceutically acceptable excipient) or carrier (e.g., pharmaceutically acceptable carrier) as described herein.
- According to yet another aspect, the present disclosure provides a method of treating or preventing hypoglycemia or a hypoglycemia related disorder or disease. The method comprises: administering an effective amount of the pro-drug peptide of the present disclosure or the pharmaceutical composition of the present disclosure, wherein the pro-drug peptide comprises a parent peptide or peptidomimetic that has an amino acid sequence that has at least 60% identity (e.g., at least 65%, 70%, 75%, 80%, 85%, 90%, 92.5%, 95%, 97.5%, 98%, 99%, or 100% identical) with glycogen. For example, the peptide or peptidomimetic may comprise an amino acid sequence that has at least 60% identity (e.g., at least 65%, 70%, 75%, 80%, 85%, 90%, 92.5%, 95%, 97.5%, 98%, 99%, or 100% identical)with the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, and the pro-drug is effective at treating or preventing hypoglycemia or the hypoglycemia related disorder or disease.
- According to a further aspect, the present disclosure provides a method of preparing a pro-drug peptide or salt thereof (e.g., a pharmaceutical salt thereof) having improved biological property or properties (e.g., at least one biological property selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism) relative to a parent peptide or peptidomimetic. The method comprises: adding a pro-drug portion to the parent peptide or peptidomimetic (e.g., synthesizing the prodrug peptide by solid-phase synthesis or liquid-phase synthesis, wherein the pro-drug portion is located at the amino-terminus or the carboxyl-terminus of the parent peptide or peptidomimetic), wherein the pro-drug portion comprises ≥2 amino acids that are cleaved in vivo releasing the peptide or peptidomimetic.
- In some embodiments, the pro-drug portion has the following structure: (Glu-Pro)m or (Lys-Pro)X, wherein X is an integer ≥1 (e.g., X is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more). For example, the pro-drug portion may be selected from the group consisting of EP, KP, EPEP, KPKP, EPEPEP, and KPKPKP.
- In certain embodiments, at least the first Lys of the pro-drug portion is functionalized with a soluble compound or moiety. In additional embodiments, at least two Lys of the pro-drug portion are functionalized with a soluble compound or moiety. In particular embodiments, the pro-drug portion comprises two amino acids, and the first amino acid is functionalized with a soluble compound or moiety. The soluble compound or moiety may be hydrophilic or soluble in aqueous solution.
- In any embodiment described herein, the first amino acid or the first Lys of the pro-drug portion may be functionalized with a soluble compound or moiety comprising: 12-aminododecanoic acid (Ado), Ado-Ado-(Lys)m, 8-amino-3,6-dioxaoctanoic acid (8Ado), 8Ado-8Ado-(Lys)m, (Lys)m, or (Pro-Lys)m. wherein m is an integer from 0-10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10). For example, at least two Lys of the pro-drug portion may be functionalized with a soluble compound comprising: Ado, Ado-Ado-(Lys)m, 8Ado, 8Ado-8Ado-(Lys)m, (Lys)m, or (Pro-Lys)m, wherein m is an integer from 0-10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10).
- One skilled in the art will appreciate that the parent peptide or peptidomimetic may be any peptide or peptidomemtic that has therapeutic activity/effect. That is, the pro-drug portion (Z) of the present disclosure may be utilized on the amino-terminus or carboxyl-terminus of any peptide or peptidomimetic that is to be used therapeutically thereby improving at least one biological property of the peptide or peptidomimetic selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism.
- For example, the parent peptide or peptidomimetic may have an amino acid sequence that is at least 85% identical (e.g., about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%) to a sequence selected from the group consisting of SEQ ID NO: 1 (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) and SEQ ID NO: 2 (HSQGTFTSDYSKYLDSRRAQDFVQWLLNT).
- The method may further comprise amidating the c-terminus of the peptide or modifying the c-terminus of the protein with an amine.
- In any of the aspects or embodiments described herein, the peptide(s) provided by the present disclosure can be present in a form of a salt known to a person skilled in the art, such as, e.g., sodium salts, ammonium salts, calcium salts, magnesium salts, potassium salts, acetate salts, carbonate salts, citrate salts, chloride salts, sulphate salts, amino chlorhydate salts, borhydrate salts, benzensulphonate salts, phosphate salts, dihydrogenophosphate salts, succinate salts, citrate salts, tartrate salts, lactate salts, mandelate salts, methane sulfonate salts (mesylate) or p-toluene sulfonate salts (tosylate). This list is provided by way of example and is not meant to be limiting on the present invention. For example, the skilled person can easily determine, according to his knowledge, the appropriate salt.
- Chemical synthesis may be performed by any method one skilled in the art would appreciate is effective at synthesizing the pro-drug peptides described herein. For example, the pro-drug peptide may be polymerized by adding the required amino acids or molecules. A method is disclosed in the example section.
- Pharmaceutical Compositions
- In another aspect the present description provides compositions comprising an effective amount of one or more of the peptides as described herein, and an excipient or carrier. Thus, in additional embodiments, the description also provides pharmaceutical compositions comprising at least one pro-drug peptide as described herein, or a combination product as described above, further including a pharmaceutically acceptable carrier.
- The pro-drug peptides (also referred to herein as “active compounds”) as described herein can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise peptide and a pharmaceutically acceptable carrier. As used herein the language “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds (e.g., additional bioactive agent) can also be incorporated into the compositions.
- The description provides methods for preparing pharmaceutical compositions. Such methods comprise formulating a pharmaceutically acceptable carrier with at least one pro-drug peptide as described herein. Such compositions can further include additional active agents as described above. Thus, the invention further includes methods for preparing a pharmaceutical composition by formulating a pharmaceutically acceptable carrier with at least one pro-drug peptide (e.g., 1, 2, 3, 4, or 5) as described herein, and one or more additional active compounds (e.g., 1, 2, 3, 4, or 5).
- A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral, nasal (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol; antioxidants such as ascorbic acid or sodium bisulfate; chelating agents such as ethylenediamine-tetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic.
- Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL (BASF; Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, chlorobutanol, phenol, ascorbic acid, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, or sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a pro-drug peptide) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium, and then incorporating the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed
- For administration by inhalation, the compounds are delivered in the form of an aerosol spray from a pressurized container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
- Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
- The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
- In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes having monoclonal antibodies incorporated therein or thereon) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.
- It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
- In certain embodiments of the methods provided herein, the method includes the step of administering a dosage from about 100 ng to about 5 mg of a therapeutic or pharmaceutical composition as described herein. In certain embodiments, e.g., in human, the pharmaceutical composition as described herein may contain mannitol as carrier, and the composition is administered from 10 μg to 500 μg, preferably 200 μg, in a single administration.
- In certain additional aspects, the dosage regimen can be reproduced from 1 to 3 times/week, every week to every four week for as long as needed with therapeutic windows and thus for several years. In a preferred embodiment, the dosage regimen is once every 4 weeks of treatment but can be repeated twice a year for several years. An example of administration is: one injection of 200 μg of peptide, every 4 weeks, for 12 weeks (i.e. 3 injections separated from each other by 4 weeks). The treatment can be prolonged by administration every 6 months.
- Preferred pharmaceutically acceptable carriers can comprise, for example, xanthan gum, locust bean gum, galactose, other saccharides, oligosaccharides and/or polysaccharides, starch, starch fragments, dextrins, British gum and mixtures thereof. Advantageously, the pharmaceutically acceptable carrier is of natural origin. The pharmaceutically acceptable carrier can be, or can further comprise, an inert saccharide diluent selected from a monosaccharide or disaccharide. Advantageous saccharide is mannitol.
- Advantageously, the invention relates to a pharmaceutical composition as defined above, which is in the form of a liposome, or nano particles, or in the form of a solution. An advantageous solution is a solution comprising from 1 to 15%, in particular about 10% of mannitol. The solution should be iso-osmolar.
- The invention also relates to a drug comprising a combination product as defined above, for a simultaneous, separate or sequential use.
- Therapeutic Methods
- In an additional aspect, the present description provides methods for treating, preventing, and/or ameliorating the symptoms of hypoglycemia or a hypoglycemia-related disease or disorder. The method comprising administering an effective amount of the pro-drug peptides of the present disclosure or the pharmaceutical or therapeutic composition of the present disclosure to a subject in need thereof, wherein the composition is effective for treating, preventing and/or ameliorating at least one symptom of hypoglycemia or a hypoglycemia-related disease or disorder. In certain embodiments, the disease or disorder is insulin-induced hypoglycemia.
- The description also provides a pro-drug peptide comprising a peptide or peptidomimetic as described herein and a prodrug portion as described herein for its use as drug, in particular for the treatment of hypoglycemia or a hypoglycemia-related disease or disorder.
- One skilled in the art will appreciate that there are numerous ways in which to prepare the pro-drug peptide or peptidomimetic of the present disclosure. For example, one could utilize standard Fmoc/Boc protected solid phase peptide synthesis. As such, when the amine on the side chain of a lysine is functionalize, one can either switch the Fmoc/Boc protecting groups of the amines of the N-terminal lysine if it is the last amino acid, or if using an Alloc lysine, if this lysine is not the last one and a Boc on the N-terminal of the last amino acid. The Alloc at the end of the sequence would then be removed with Pd(o) and the amine functionalized.
- General Procedure for Peptide Synthesis. The synthesis of peptides 1-9, which respectively correspond to SEQ ID NOs: 2-5, 8-10, 6 and 7, was conducted on automated peptide synthesizer LibertyBlue from CEM Company using Fmoc solid phase strategy with PyBop and DIEA as coupling reagents according to previously reported procedures. Merrifield, R. B. J. Am. Chem. Soc. 1963, 85, 2149-2154; Palasek S. A., Cox Z. J., Collins J. M. J. Pept. Sci. 2007; 13, 143-148; Douat-Casassus C. Pulka K, Claudon P. Guichard G, Org. Lett. 2012, 14, 3130-3133.
- Solubility Analysis of Exemplary Peptides. A solution of 3 mg/mL of peptide or peptidomimetic (glucagon or analog thereof) was prepared in a 0.01M HCl solution. Then 0.1 mL of the stock solution was diluted to 1 mL with HCl (0.01M) and the UV absorbance was measured (to 280 nm) with nanodrop UV spectrometer (
NanoDrop 1000 from Thermo Fischer Company). The pH of the remaining stock solution was adjusted topH 7 using Na2HPO4 (0.1M) and the solution was allowed to stand overnight at 4° C. Then the solution was centrifuged three times (5 min, 4000 min−1), 0.1 mL of the supernatant was removed and diluted to 1 mL with HCl solution (0.01M). The final UV absorbance was measured. - The solubility was assessed by the following calculation:
-
(Final Absorbance/Initial Absorbance)×3 mg/mL=Solubility (mg/mL). -
TABLE 1 solubility and stabilities of peptides 1 to 7Solubility in Compound Water (mg/ml) 1 0.24 2 0.35 3 1.2 4 1.74 5 1.78 6 0.53 7 1.06 - Stability Analysis of Exemplary Peptides. A solution of 1 mg/mL of peptide or peptidomimetic (glucagon or analog thereof) was prepared in water or physiological serum and stored at room temperature or at 4° C. The samples were analyzed by high-performance liquid chromatography (HPLC) with 10 to 100% CH3CN (+0.1% trifluoroacetic acid (TFA) v/v) in water (+0.1% TFA v/v) in 10 minutes as gradient. The HPLC column (
EC 100/4 NUCLEODUR 100-3 C18ec) was purchased to Macherey-Nagel Company. -
Peptides FIGS. 5-7, and 9 in water, PBS, and physiological serum. - In Vivo Analysis of Exemplary Glucagon-Based Peptides. The 18 animals (rats, males, 8-week old) were housed in ventilated and enriched housing cages (310×125×127 mm3) throughout the experimental phase. They were housed in groups of 3 animals during the study, on a normal 12 hours light cycle (at 08:00 pm lights off), 22±2° C. and 50±10% relative humidity. They were acclimated for 5 days with standard diet and tap water. Then, after 3 hours fasting, the animals were treated with glucagon or
analogs - The Exemplary peptides demonstrated better ability to raise blood glucose over the course of treatment, relative to the glucagon control, as well as the inactive peptide and vehicle control.
- Detailed Procedures for Peptide Synthesis.
- A1: Rink amide (≈200 mg, loading 0.5 mmol/g) or Sieber resin (≈160mg, loading 0.62 mmol/g) was swelled in dimethyl formaldehyde (DMF; 3 mL) for 30 minutes. Peptide synthesis was then conducted with an automated peptide synthesizer (LibertyBlue from CEM Company) using Fmoc solid phase strategy with PyBop (5 eq. relative to the resin loading) and N,N-diisopropylethylamine (DIEA; 10 eq. relative to the resin loading) as coupling reagents according to previously reported procedures (Merrifield, R. B. J. Am. Chem. Soc. 1963, 85, 2149-2154; Palasek S. A., Cox Z. J., Collins J. M. J. Pept. Sci. 2007; 13, 143-148).
- A2: Wang resin (≈220 mg, loading 0.4 mmol/g) was swelled in DMF (3 mL) for 30 minutes. First amino-acid (5 eq.) was dissolved in dry dichloromethane (DCM; 3 mL) under inert atmosphere. N,N′-dicyclohexylcarbodiimide (DCC; 2.5 eq.) was added and the mixture was stirred 20 minutes at 0° C. before DCM concentration and DMF addition. The mixture was loaded on the swollen Wang resin with a small amount of 4-dimethylaminopyridine (DMAP). The resin was shacked for 2 hours at room temperature then filtrated and washed three times with DMF, DCM and MeOH. Then the peptide was synthesized according to procedure A1 or A2.
- B: Alloc deprotection: resin was swollen in DCM for 30 minutes then Pd(Ph3)4 (0.25 eq.) and phenylsilane (10 eq.) were added. The mixture was stirred at room temperature for 45 minutes then the resin is filtrated and wash 3 times with DCM.
- Cleavage Procedures:
- C1: After completion of the synthesis, the resin was transferred into a syringe with a frit, and washed three times with DMF, three times with CH2Cl2 and three times with Et2O. Cleavage from the resin was performed using 88% TFA with 2
% triisopropylsilane 5% phenol and 5% water (3 mL). After 2 hours the resin was filtered and discarded. Diethyl ether was added to precipitate the oligomer and the solid was triturated and filtrated. - C2: After completion of the synthesis, the resin was transferred into a syringe with a frit, and washed three times with DMF, three times with CH2Cl2 and three times with Et2O. Cleavage from the resin was performed using 88% TFA with 2.5% triisopropylsilane and 2.5% water (3 mL). After 2 hours the resin was filtered and discarded. Diethyl ether was added to precipitate the oligomer and the solid was triturated and filtrated.
- General Procedure for Purification. All the peptides were purified by semi preparative HPLC on a Dionex U3000SD using a Macherey-Nagel Nucleodur C18ec column (10×250 mm, 5 μm) at a flow rate of 4 mL/min with UV detection at 200 nm. The mobile phase was composed of 0.1% (v/v) TFA-H2O (Solvent A) and 0.1% (v/v) TFA-CH3CN (solvent B).
- General Procedure for Analysis. Peptides 10-25, which respectfully correspond to SEQ ID NOs:1 and 14-28, were analyzed by analytical RP-HPLC on a Dionex U3000SD using a Macherey-Nagel Nucleodur C 18ec column (4×100 mm, 3 μm) at a flow rate of 1 mL/min with UV detection at 200 nm. The mobile phase was composed of 0.1% (v/v) TFA-H2O (Solvent A) and 0.1% (v/v) TFA-CH3CN (solvent B). Liquid chromatography-mass spectrometry (LC-MS) analyses were carried out on a ultra-high performance liquid chromatography (UHPLC; Agilent 1290 Infinity) coupled to an electrospray ionization time-of-flight (ESI-TOF) mass spectrometer (Agilent 6230 ESI).
- Solubility Assay. A solution of the compound (e.g., glucagon or analogues thereof) was prepared in a 0.01M HCl solution. Then 0.1 mL of the stock solution was diluted to 1 mL with HCl (0.01M) and the UV absorbance was measured (to 280 nm) with NanoDrop UV spectrometer (
NanoDrop 1000 from Thermo Fischer Company). The pH of the remaining stock solution was adjusted topH 7 using Na2HPO4 (0.1M) and the solution was allowed to stand overnight at 4° C. Then the solution was centrifuged three times (5 min, 4000 min−1), 0.1 mL of the supernatant was removed and diluted to 1 mL with HCl solution (0.01M). The final UV absorbance was measured. The solubility was accessible by the following formula: -
(Final Absorbance/Initial Absorbance)×100=Percent Soluble - The percent solubility of glucagon and exemplary peptides is shown in Table 2. As can be seen by the data of Table 2, the exemplary glucagon analogues have greater solubility as compared to glucagon.
-
TABLE 2 Solubility of Glucagon and analogues thereof in PBS buffer (0.1M) at pH 7.4 Solubility at Solubility at Compound 1 mg/mL (%) 25 mg/mL (%) 10 15 11 17 12 20 13 56 14 77 16 80 17 82 18 18 19 92 88 21 92 22 34 23 79 25 75 92 - Stability Assay. A solution of 1 mg/mL of peptide or peptidomimetic (glucagon or analog thereof) was prepared in a NaCl 0.9% aqueous solution and stored at room temperature, or 4° C., or 37° C. and or 50° C. The samples were analyzed by RP-HPLC on a Dionex U3000SD using a Macherey-Nagel Nucleodur C18ec column (4×100 mm, 3 μm) at a flow rate of 1 mL/min with UV detection at 200 nm. The mobile phase was composed of 0.1% (v/v) TFA-H2O (Solvent A) and 0.1% (v/v) TFA-CH3CN (Solvent B). The percent of exemplary peptide or glucagon remaining after incubation at varying temperatures and times is shown in Table 3.
-
TABLE 3 Percentage of peptide remaining in an aqueous solution of NaCl 0.9% at different temperatures after different times (T0 = 100%) Compound T° C. 1 week 1 month 5 months 10 RT 95 85 0 10 4° C. 91 86 0 13 RT 97 95 84 13 4° C. 98 98 93 14 RT 99 97 87 14 4° C. 99 99 97 16 RT 95 94 80 16 4° C. 97 95 90 17 RT 97 95 86 17 4° C. 96 96 91 19 RT 100 97 89 19 4° C. 100 100 95 19 37° C. 95 86 — 19 50° C. 79 65 — 19 70° C. 16 0 — 21 RT 94 — — 21 37° C. 88 69 — 21 50° C. 81 58 — 21 70° C. 24 — — 24 RT 97 94 81 24 4° C. 97 97 92 24 37° C. 89 78 — 24 50° C. 84 67 — 25 RT 98 98 86 25 4° C. 100 100 93 25 37° C. 86 71 — 25 50° C. 77 53 — - Rat Studies. The rats (Wistar Rat, males, 8-week old, n=6 or 3) were housed in ventilated and enriched housing cages (310×125×127 mm3) throughout the experimental phase. They were housed in groups of 3 animals during the study, on a normal 12 hours light cycle (lights off at 08:00 PM), 22±2° C. and 50±10% relative humidity. The rates were acclimated for 5 days with standard diet and tap water. Then, after 3 hours fasting, they were treated with glucagon (10) or
analogs FIGS. 12 and 13 . As shown inFIGS. 12 and 13 , the glucagon analogs provided greater glycogen breakdown, compared to glucagon, as demonstrated by the increased blood glucose levels in the rats. - Peptide Characterization.
-
Peptide 10: HSQGTFTSDYSKYLDSRRAQDFVQWLMNT-OH -
Peptide 10 was synthesized using the general procedure A2 starting from Wang resin (196 mg, 0.1 mmol) and cleaved using procedure C2. Thefinal product 10 was purified by semi-preparative HPLC. 1.88 mg was obtained (yield 0.54%). HPLC: Rt=5.03 min (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18); LC-MS (m/z 3482.40): 697.48 [M+5H]5+, 871.36 [M+4H]4+, 1161.82 [M+3H]3+. -
Peptide 11: HSQGTFTSDYSKYLDSRRAQDFVQWLMNT-NH2 - Peptide 11 was synthesized using the general procedure A1 starting from Sieber resin (160 mg, 0.1 mmol) and cleaved using procedure C2. The final product 11 was purified by semi-preparative HPLC. 1.59 mg was obtained (yield 0.45%). HPLC: Rt=5.03 min (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18); LC-MS (m/z 3481.75): 697.35 [M+5H]5+, 871.44 [M+4H]4+, 1161.59 [M+3H]3+.
-
Peptide 12: KPHSQGTFTSDYSKYLDSRRAQDFVQWLLNT-NH2 - Peptide 12 was synthesized using the general procedure A1 starting from Sieber resin (160 mg, 0.1 mmol) and cleaved using procedure C1. The final product 12 was purified by semi-preparative HPLC. 9.26 mg was obtained (yield 2.50%). HPLC: Rt=5.06 min (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18); LC-MS (m/z 3688.65): 615.77 [M+6H]6+ 738.73 [M+5H]5+, 923.17 [M+4H]4+, 1230.57 [M+3H]3+.
-
Peptide 13: KPKPHSQGTFTSDYSKYLDSRRAQDFVQWLLNT-NH2 - Peptide 13 was synthesized using the general procedure A1 starting from Sieber resin (160 mg, 0.1 mmol) and cleaved using procedure C1. The final product 13 was purified by semi-preparative HPLC. 16.0 mg was obtained (yield 4.1%). HPLC: Rt=5.06 min (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18); LC-MS (m/z 3914.15): 653.36 [M+6H]6+ 783.83 [M+5H]5+, 979.53 [M+4H]4+.
-
Peptide 14: KPKPKPHSQGTFTSDYSKYLDSRRAQDFVQWLLNT-NH2 -
Peptide 14 was synthesized using the general procedure A1 starting from Sieber resin (160 mg, 0.1 mmol) and cleaved using procedure C1. Thefinal product 14 was purified by semi-preparative HPLC. 8.0 mg was obtained (yield 1.9%). HPLC: Rt=4.91 min (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18); LC-MS (m/z 4138.20): 592.16 [M+7H]7+ 690.7 [M+6H]6+ 828.66 [M+5H]5+, 1035.60 [M+4H]4+. -
Peptide 15: KPHSQGTFTSDYSKYLDSRRAQDFVQWLMNT-NH2 -
Peptide 15 was synthesized using the general procedure A1 starting from Sieber resin (160 mg, 0.1 mmol) and cleaved using procedure C2. Thefinal product 15 was purified by semi-preparative HPLC. 2.86 mg was obtained (yield 0.77%). HPLC: Rt=5.01 min (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18); LC-MS (m/z 3706.93): 618.82 [M+6H]6+ 742.39 [M+5H]5+, 927.73 [M+4H]4+. -
Peptide 16: KPKPHSQGTFTSDYSKYLDSRRAQDFVQWLMNT-NH2 - Peptide 16 was synthesized using the general procedure A1 starting from Sieber resin (160 mg, 0.1 mmol) and cleaved using procedure C2. The final product 16 was purified by semi-preparative HPLC. 6.48 mg was obtained (yield 1.6%). HPLC: Rt=4.94 min (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18); LC-MS (m/z 3932.1): 656.35 [M+6H]6+ 787.42 [M+5H]5+, 984.02 [M+4H]4+.
-
Peptide 17: KPKPKPHSQGTFTSDYSKYLDSRRAQDFVQWLMNT-NH2 - Peptide 17 was synthesized using the general procedure A1 starting from Sieber resin (160 mg, 0.1 mmol) and cleaved using procedure C2. The final product 17 was purified by semi-preparative HPLC. 7.99 mg was obtained (yield 1.9%). HPLC: Rt=4.93 min (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18); LC-MS (m/z 4157.22): 594.89 [M+7H]7+ 693.87 [M+6H]6+ 832.45 [M+5H]5+, 1040.31 [M+4H]4+.
-
Peptide 18: EPHSQGTFTSDYSKYLDSRRAQDFVQWLLNT-NH2 -
Peptide 18 was synthesized using the general procedure A1 starting from Sieber resin (160 mg, 0.1 mmol) and cleaved using procedure C1. Thefinal product 18 was purified by semi-preparative HPLC. 8.07 mg was obtained (yield 2.2%). HPLC: Rt=5.04 min (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18); LC-MS (m/z 3689.19): 738.8 [M+5H]5+, 923.27 [M+4H]4+, 1230.73 [M+3H]3+. -
Peptide 19: K*PHSQGTFTSDYSKYLDSRRAQDFVQWLLNT-NH2, - wherein K* is a lysine modified with KKKKKK
-
Peptide 19 was synthesized using the general procedure A1 starting from Sieber resin (160 mg, 0.1 mmol) and cleaved using procedure C1. Thefinal product 19 was purified by semi-preparative HPLC. 17.15 mg was obtained (yield 3.8%). HPLC: Rt=4.62 min (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18); LC-MS (m/z 4457.46): 637.78 [M+7H]7+, 743.91 [M+6H]6+, 892.49 [M+5H]5+, 1115.36 [M+4H]4+. -
Peptide 20: K*PHSQGTFTSDYSKYLDSRRAQDFVQWLMNT-NH2, - wherein K* is a lysine modified with KKKKKK
-
Peptide 20 was synthesized using the general procedure A1 starting from Rink resin (227 mg, 0.1 mmol) and cleaved using procedure C2. Thefinal product 20 was purified by semi-preparative HPLC. 1.9 mg was obtained (yield 0.4%). HPLC: Rt=4.54 min (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18); LC-MS (m/z 4476.18): 560.54 [M+8H]8+, 640.46 [M+7H]7+, 747.03 [M+6H]6+, 896.22 [M+5H]5+, 1120.00 [M+4H]4+. -
Peptide 21: K*PHSQGTFTSDYSKYLDSRRAQDFVQWLMNT-OH, - wherein K* is a lysine modified with KKKKKK
- Peptide 21 was synthesized using the general procedure A2 starting from Wang resin (227 mg, 0.1 mmol) cleaved using procedure C2. The final product 21 was purified by semi-preparative HPLC. 28.11 mg was obtained (yield 6.3%). HPLC: Rt=4.63 min (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18); LC-MS (m/z 4477.14): 640.36 [M+7H]7+, 746.93 [M+6H]6+, 896.14 [M+5H]5+, 1119.93 [M+4H]4+
-
Peptide 22: K*PHSQGTFTSDYSKYLDSRRAQDFVQWLLNT-NH2, - wherein K* is a lysine modified with 8Ado8Ado
- Peptide 22 was synthesized using the general procedure A1 starting from Sieber resin (227 mg, 0.1 mmol) cleaved using procedure C1. The final product 22 was purified by semi-preparative HPLC. 1.9 mg was obtained (yield 0.4%). HPLC: Rt=4.96 min (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18); LC-MS (m/z 3978.06): 644.01 [M+6H]6+, 796.63 [M+5H]5+, 995.57 [M+4H]4+, 1326.79 [M+3H]3+.
-
Peptide 23: K*PHSQGTFTSDYSKYLDSRRAQDFVQWLLNT-NH2, - wherein K*is a lysine modified with KKKKKK8Ado8Ado
- Peptide 23 was synthesized using the general procedure A1 starting from Sieber resin (227 mg, 0.1 mmol) and cleaved using procedure C1. The final product 23 was purified by semi-preparative HPLC. 11.99 mg was obtained (yield 2.5%). HPLC: Rt=4.78 min (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18); LC-MS (m/z 4748.44): 594.30 [M+8H]8+, 679.07 [M+7H]7+, 792.09 [M+5H]5+, 950.3 [M+4H]4+.
-
Peptide 24: K*PHSQGTFTSDYSKYLDSRRAQDFVQWLMNT-NH2, - wherein K* is a lysine modified with KPKPKP
- Peptide 24 was synthesized using the general procedure A1 starting from Rink resin (227 mg, 0.1 mmol) and cleaved using procedure C2. The final product 24 was purified by semi-preparative HPLC. 5.0 mg was obtained (yield 1.1%). HPLC: Rt=4.91 min (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18); LC-MS (m/z 4382.98): 627.17 [M+7H]7+, 731.58 [M+6H]6+, 877.58 [M+5H]5+, 1096.75 [M+4H]4+.
-
Peptide 25: K*PHSQGTFTSDYSKYLDSRRAQDFVQWLMNT-OH, - wherein K* is a lysine modified with KPKPKP.
-
Peptide 25 was synthesized using the general procedure A2 starting from Wang resin (216 mg, 0.1 mmol) and cleaved using procedure C2. Thefinal product 25 was purified by semi-preparative HPLC. 7.02 mg was obtained (yield 1.6%). HPLC: Rt=4.86 min (10-100%; CH3CN 0.1% TFA in H2O 0.1% TFA, 10 min, C18); LC-MS (m/z 4383.96): 627.14 [M+7H]7+, 731.50 [M+6H]6+, 877.60 [M+5H]5+, 1096.76 [M+4H]4+. - According to an aspect, the present disclosure provides a pro-drug peptide or salt thereof having improvement for at least one biological property relative to a parent peptide or peptidomimetic, wherein the biological property is selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism, the pro-drug peptide comprising the following structure: Zn-pep, wherein: pep is the parent peptide or peptidomimetic; Z is a sequence of n amino acids, wherein Z is cleaved in vivo releasing pep, and n is an integer 2 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more).
- In any aspect or embodiment described herein, the Z has the following structure: (Glu-Pro)m or (Lys-Pro)X, wherein X is an integer ≥1 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more).
- In any aspect or embodiment described herein, the Z is selected from the group consisting of EP, KP, EPEP, KPKP, EPEPEP, and KPKPKP.
- In any aspect or embodiment described herein, at least the first Lys of Z is functionalized with a soluble compound.
- In any aspect or embodiment described herein, at least two Lys of Z are functionalized with the soluble compound.
- In any aspect or embodiment described herein, the Z comprises two amino acids, and the first amino acid is functionalized with a soluble compound.
- In any aspect or embodiment described herein, the soluble compound is aqueously soluble.
- In any aspect or embodiment described herein, the first amino acid of Z is functionalized with a soluble compound or moiety comprising: 12-aminododecanoic acid (Ado), Ado-Ado-(Lys)m, 8-amino-3,6-dioxaoctanoic acid (8Ado), 8Ado-8Ado-(Lys)m, (Lys)m, or (Pro-Lys)m, wherein m is an integer from 0-10.
- In any aspect or embodiment described herein, at least two Lys of Z are functionalized with a soluble compound or moiety comprising: Ado, Ado-Ado-(Lys)m, 8Ado, 8Ado-8Ado-(Lys)m, (Lys)m, or (Pro-Lys)m. wherein m is an integer from 0-10.
- In any aspect or embodiment described herein, the c-terminus of the peptide is amine modified or amidated.
- In any aspect or embodiment described herein, the parent peptide or peptidomimetic has an amino acid sequence that is at least 85% identical to a sequence selected from the group consisting of SEQ ID NO: 1 (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) and SEQ ID NO: 2 (HSQGTFTSDYSKYLDSRRAQDFVQWLLNT).
- According to another aspect, the present disclosure provides a pharmaceutical composition comprising: an effective amount of the pro-drug of the present disclosure, and a pharmaceutically acceptable excipient or carrier.
- According to yet another aspect, the present disclosure provides a method of treating or preventing hypoglycemia or a hypoglycemia related disorder or disease, the method comprising: administering an effective amount of the pro-drug peptide of the present disclosure or the pharmaceutical composition of the present disclosure, wherein the pro-drug peptide is effective at treating or preventing hypoglycemia or the hypoglycemia related disorder or disease.
- According to a further aspect, the present disclosure provides a method of preparing a pro-drug peptide or salt thereof having improvement for at least one biological property relative to a parent peptide or peptidomimetic, wherein the biological property is selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism. The method comprising: adding a pro-drug portion to the parent peptide or peptidomimetic, wherein the pro-drug portion comprises ≥2 amino acids that are cleaved in vivo releasing the peptide or peptidomimetic.
- In any aspect or embodiment described herein, the pro-drug portion has the following structure: (Glu-Pro)m or (Lys-Pro)X, wherein X is ≥1 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more).
- In any aspect or embodiment described herein, the pro-drug portion is selected from the group consisting of EP, KP, EPEP, KPKP, EPEPEP, and KPKPKP.
- In any aspect or embodiment described herein, at least the first Lys of the pro-drug portion is functionalized with a soluble compound or moiety.
- In any aspect or embodiment described herein, at least two Lys of the pro-drug portion are functionalized with the soluble compound or moiety.
- In any aspect or embodiment described herein, the pro-drug portion comprises two amino acids, and the first amino acid is functionalized with the soluble compound or moiety.
- In any aspect or embodiment described herein, the soluble compound is hydrophilic (i.e., soluble in aqueous solution).
- In any aspect or embodiment described herein, the first amino acid of the pro-drug portion is functionalized with a soluble compound or moiety comprising: 12-aminododecanoic acid (Ado), Ado-Ado-(Lys)m, 8-amino-3,6-dioxaoctanoic acid (8Ado), 8Ado-8Ado-(Lys)m, (Lys)m, or (Pro-Lys)m. wherein m is an integer from 0-10.
- In any aspect or embodiment described herein, at least two Lys of the pro-drug portion is functionalized with a soluble compound or moiety comprising: Ado, Ado-Ado-(Lys)m, 8Ado, 8Ado-8Ado-(Lys)m, (Lys)m, or (Pro-Lys)m, wherein m is an integer from 0-10.
- In any aspect or embodiment described herein, the c-terminus of the peptide is amine modified or amidated.
- In any aspect or embodiment described herein, the parent peptide or peptidomimetic has an amino acid sequence that is at least 85% identical to a sequence selected from the group consisting of SEQ ID NO: 1 (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) and SEQ ID NO: 2 (HSQGTFTSDYSKYLDSRRAQDFVQWLLNT).
- In any aspect or embodiment describe herein, the peptide or peptidomimetic includes or is a peptide selected from SEQ ID NO: 3-10 and 11-25.
- In any aspect or embodiment described herein, the peptide or peptidomimetic includes or is elected from 2-9 and 11-25.
- While preferred embodiments of the invention have been shown and described herein, it will be understood that such embodiments are provided by way of example only. Numerous variations, changes and substitutions will occur to those skilled in the art without departing from the spirit of the invention. Accordingly, it is intended that the appended claims cover all such variations as fall within the spirit and scope of the invention.
- The contents of all references, patents, pending patent applications and published patents, cited throughout this application are hereby expressly incorporated by reference.
- Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims. It is understood that the detailed examples and embodiments described herein are given by way of example for illustrative purposes only, and are in no way considered to be limiting to the invention. Various modifications or changes in light thereof will be suggested to persons skilled in the art and are included within the spirit and purview of this application and are considered within the scope of the appended claims. For example, the relative quantities of the ingredients may be varied to optimize the desired effects, additional ingredients may be added, and/or similar ingredients may be substituted for one or more of the ingredients described. Additional advantageous features and functionalities associated with the systems, methods, and processes of the present invention will be apparent from the appended claims. Moreover, those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
Claims (20)
1. A pro-drug peptide or salt thereof having improvement for at least one biological property relative to a parent peptide or peptidomimetic, wherein the biological property is selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism, the pro-drug peptide comprising the following structure:
Zn-pep,
Zn-pep,
wherein:
pep is the parent peptide or peptidomimetic;
Z is a sequence of n amino acids, which is cleaved in vivo releasing pep; and
n is an integer ≥2.
2. The pro-drug peptide of claim 2 , wherein the Z has the following structure: (Glu-Pro)m or (Lys-Pro)X, wherein X is an integer ≥1.
3. The pro-drug peptide of claim 1 , wherein the Z is selected from the group consisting of EP, KP, EPEP, KPKP, EPEPEP, and KPKPKP.
4. The pro-drug peptide of claim 2 , wherein at least the first Lys of Z is functionalized with a soluble compound or moiety.
5. The pro-drug peptide of claim 2 , wherein at least two Lys of Z are functionalized with the soluble compound or moiety.
6. The pro-drug peptide of claim 1 , wherein the Z comprises two amino acids, and the first amino acid is functionalized with a soluble compound or moiety.
7. The pro-drug peptide of claim 4 , wherein the soluble compound or moiety is hydrophilic.
8. The pro-drug peptide of claim 1 , wherein the first amino acid of Z is functionalized with a soluble compound or moiety comprising: 12-aminododecanoic acid (Ado), Ado-Ado-(Lys)m, 8-amino-3,6-dioxaoctanoic acid (8Ado), 8Ado-8Ado-(Lys)m, (Lys)m, or (Pro-Lys)m, wherein m is an integer from 0-10.
9. The pro-drug peptide of claim 2 , wherein at least two Lys of Z are functionalized with a soluble compound or moiety comprising: Ado, Ado-Ado-(Lys)m, 8Ado, 8Ado-8Ado-(Lys)m, (Lys)m, or (Pro-Lys)m. wherein m is an integer from 0-10.
10. The pro-drug peptide of claim 1 , wherein the c-terminus of the peptide is amine modified.
11. The pro-drug peptide of claim 1 , wherein the parent peptide or peptidomimetic has an amino acid sequence that is at least 85% identical to a sequence selected from the group consisting of SEQ ID NO: 1 (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) and SEQ ID NO: 2 (HSQGTFTSDYSKYLDSRRAQDFVQWLLNT).
12. A pharmaceutical composition comprising: an effective amount of the pro-drug of claim 1 , and a pharmaceutically acceptable excipient or carrier.
13. A method of treating or preventing hypoglycemia or a hypoglycemia related disorder or disease, the method comprising: administering an effective amount of the the pharmaceutical composition of claim 12 , wherein the pro-drug peptide is effective at treating or preventing hypoglycemia or the hypoglycemia related disorder or disease.
14. A method of preparing a pro-drug peptide or salt thereof having improvement for at least one biological property relative to a parent peptide or peptidomimetic, wherein the biological property is selected from the group consisting of therapeutic index, stability, solubility, toxicity, adsorption, and pre-systemic metabolism, the method comprising:
adding a pro-drug portion to the parent peptide or peptidomimetic,
wherein the pro-drug portion comprises ≥2 amino acids that are cleaved in vivo releasing the peptide or peptidomimetic.
15. The method of claim 14 , wherein:
the pro-drug portion has the following structure: (Glu-Pro)m or (Lys-Pro)X, wherein X is ≥1;
the pro-drug portion is selected from the group consisting of EP, KP, EPEP, KPKP, EPEPEP, and KPKPKP;
the first amino acid of the pro-drug portion is functionalized with a soluble compound or moiety comprising: 12-aminododecanoic acid (Ado), Ado-Ado-(Lys)m, 8-amino-3,6-dioxaoctanoic acid (8Ado), 8Ado-8Ado-(Lys)m, (Lys)m, or (Pro-Lys)m. wherein m is an integer from 0-10;
the parent peptide or peptidomimetic has an amino acid sequence that is at least 85% identical to a sequence selected from the group consisting of SEQ ID NO: 1 (HSQGTFTSDYSKYLDSRRAQDFVQWLMNT) and SEQ ID NO: 2 (HSQGTFTSDYSKYLDSRRAQDFVQWLLNT);
the method further comprises amidating the c-terminus of the peptide or modifying the c-terminus of the protein with an amine; or
a combination thereof.
16. The method of claim 15 , wherein at least the first Lys of the pro-drug portion is functionalized with a soluble compound.
17. The method of claim 15 , wherein at least two Lys of the pro-drug portion are functionalized with the soluble compound.
18. The method of claim 14 , wherein the pro-drug portion comprises two amino acids, and the first amino acid is functionalized with a soluble compound.
19. The method of claim 16 , wherein the soluble compound is aqueously soluble.
20. The method of claim 15 , wherein at least two Lys of the pro-drug portion is functionalized with a soluble compound or moiety comprising: Ado, Ado-Ado-(Lys)m, 8Ado, 8Ado-8Ado-(Lys)m, (Lys)m, or (Pro-Lys)m, wherein m is an integer from 0-10.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/135,627 US20210122800A1 (en) | 2017-06-29 | 2020-12-28 | Pro-drug peptide with improved pharmaceutical properties |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762526678P | 2017-06-29 | 2017-06-29 | |
US16/023,901 US10889627B2 (en) | 2017-06-29 | 2018-06-29 | Pro-drug peptide with improved pharmaceutical properties |
US17/135,627 US20210122800A1 (en) | 2017-06-29 | 2020-12-28 | Pro-drug peptide with improved pharmaceutical properties |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/023,901 Continuation US10889627B2 (en) | 2017-06-29 | 2018-06-29 | Pro-drug peptide with improved pharmaceutical properties |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210122800A1 true US20210122800A1 (en) | 2021-04-29 |
Family
ID=63684203
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/023,901 Active US10889627B2 (en) | 2017-06-29 | 2018-06-29 | Pro-drug peptide with improved pharmaceutical properties |
US17/135,627 Abandoned US20210122800A1 (en) | 2017-06-29 | 2020-12-28 | Pro-drug peptide with improved pharmaceutical properties |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/023,901 Active US10889627B2 (en) | 2017-06-29 | 2018-06-29 | Pro-drug peptide with improved pharmaceutical properties |
Country Status (11)
Country | Link |
---|---|
US (2) | US10889627B2 (en) |
EP (1) | EP3645558A2 (en) |
JP (1) | JP7046990B2 (en) |
KR (1) | KR102398777B1 (en) |
CN (1) | CN111051338A (en) |
AU (2) | AU2018293467B2 (en) |
BR (1) | BR112019028134A2 (en) |
CA (1) | CA3067674A1 (en) |
IL (1) | IL271741A (en) |
SG (1) | SG11201912433YA (en) |
WO (1) | WO2019002945A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3911960A1 (en) | 2019-01-18 | 2021-11-24 | UREKA Sarl | Peptide-oligourea hybrid compounds |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
EP0561971A1 (en) * | 1990-12-13 | 1993-09-29 | PHARMACIA & UPJOHN COMPANY | Fusion polypeptides |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
WO1999046283A1 (en) * | 1998-03-09 | 1999-09-16 | Zealand Pharmaceuticals A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
GB0310593D0 (en) * | 2003-05-08 | 2003-06-11 | Leuven K U Res & Dev | Peptidic prodrugs |
EP2390264A1 (en) * | 2005-02-11 | 2011-11-30 | Amylin Pharmaceuticals Inc. | GIP analog and hybrid polypeptides with selectable propperties |
EP1959986B1 (en) * | 2005-11-07 | 2014-07-23 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
FR2900341B1 (en) * | 2006-04-27 | 2012-09-14 | Centre Nat Rech Scient | USE OF MULTIVALENT SYNTHETIC LIGANDS OF SURFACE NUCLEOLIN FOR THE TREATMENT OF CANCER |
JP2010536341A (en) * | 2007-08-15 | 2010-12-02 | アムニクス, インコーポレイテッド | Compositions and methods for altering properties of biologically active polypeptides |
US8084597B2 (en) * | 2007-11-15 | 2011-12-27 | Molecular Kinetics Incorporated | Artificial entropic bristle domain sequences and their use in recombinant protein production |
WO2010080578A1 (en) * | 2008-12-18 | 2010-07-15 | Phasebio Pharmaceuticals, Inc. | Biologically active proteins activatable by peptidase |
US20130053310A1 (en) * | 2010-03-26 | 2013-02-28 | Novo Nordisk A/S | Novel glucagon analogues |
EP2723367B1 (en) * | 2011-06-22 | 2017-05-03 | Indiana University Research and Technology Corporation | Glucagon/glp-1 receptor co-agonists |
JP6359972B2 (en) * | 2011-11-03 | 2018-07-18 | ジーランド ファーマ アクティーゼルスカブ | GLP-1 receptor agonist peptide gastrin conjugate |
WO2013098408A1 (en) * | 2011-12-30 | 2013-07-04 | Zealand Pharma A/S | Glucagon and cck receptor agonist peptide conjugates |
EP2797619A4 (en) | 2011-12-30 | 2015-07-08 | Joslin Diabetes Center Inc | Glypican-4 based compositions and methods for treating and diagnosing insulin resistance |
SG11201405276PA (en) * | 2012-02-27 | 2014-10-30 | Amunix Operating Inc | Xten conjugate compositions and methods of making same |
ES2947409T3 (en) * | 2014-09-24 | 2023-08-08 | Univ Indiana Res & Tech Corp | Lipid amide-based insulin prodrugs |
-
2018
- 2018-06-29 EP EP18778550.6A patent/EP3645558A2/en active Pending
- 2018-06-29 CA CA3067674A patent/CA3067674A1/en active Pending
- 2018-06-29 SG SG11201912433YA patent/SG11201912433YA/en unknown
- 2018-06-29 CN CN201880056622.2A patent/CN111051338A/en active Pending
- 2018-06-29 KR KR1020207002765A patent/KR102398777B1/en active IP Right Grant
- 2018-06-29 US US16/023,901 patent/US10889627B2/en active Active
- 2018-06-29 WO PCT/IB2018/000838 patent/WO2019002945A2/en unknown
- 2018-06-29 BR BR112019028134-7A patent/BR112019028134A2/en unknown
- 2018-06-29 AU AU2018293467A patent/AU2018293467B2/en active Active
- 2018-06-29 JP JP2019572117A patent/JP7046990B2/en active Active
-
2019
- 2019-12-29 IL IL271741A patent/IL271741A/en unknown
-
2020
- 2020-12-28 US US17/135,627 patent/US20210122800A1/en not_active Abandoned
-
2021
- 2021-02-04 AU AU2021200731A patent/AU2021200731B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2019002945A3 (en) | 2019-02-21 |
AU2018293467B2 (en) | 2020-11-05 |
JP7046990B2 (en) | 2022-04-04 |
US10889627B2 (en) | 2021-01-12 |
WO2019002945A8 (en) | 2020-02-13 |
KR20200028402A (en) | 2020-03-16 |
AU2021200731A1 (en) | 2021-03-04 |
BR112019028134A2 (en) | 2020-09-29 |
CN111051338A (en) | 2020-04-21 |
AU2021200731B2 (en) | 2022-10-27 |
AU2018293467A1 (en) | 2020-02-06 |
US20190002519A1 (en) | 2019-01-03 |
CA3067674A1 (en) | 2019-01-03 |
SG11201912433YA (en) | 2020-01-30 |
EP3645558A2 (en) | 2020-05-06 |
IL271741A (en) | 2020-02-27 |
KR102398777B1 (en) | 2022-05-17 |
WO2019002945A2 (en) | 2019-01-03 |
JP2020525478A (en) | 2020-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101426070B1 (en) | 36 methods for reducing cd36 expression | |
US10456443B2 (en) | Peptidyl calcineurin inhibitors | |
KR20110114568A (en) | Dipeptide linked medicinal agents | |
JPH06504794A (en) | Novel amylin agonist peptides and their uses | |
JP5372096B2 (en) | Novel antitumor compounds | |
US20210122800A1 (en) | Pro-drug peptide with improved pharmaceutical properties | |
AU2006256439A1 (en) | New hybrid oligomers. Their preparation process and pharmaceutical compositions containing them | |
HU208027B (en) | Process for producing peptide compounds and pharmaceutical composition containing them as active components | |
CN116390723A (en) | Methods and compositions for delivery of biotin to mitochondria | |
JP4817335B2 (en) | New antibacterial peptide | |
CA3238682A1 (en) | Pentapeptide and use thereof | |
KR102084341B1 (en) | Short synthetic peptides and uses thereof | |
US20160194356A1 (en) | Aromatic-cationic peptides and uses of same | |
HU201964B (en) | Process for producing peptides inhibiting maturation of t-lymphocytes and activity of macrophages, as well as pharmaceutical compositions comprising same | |
JP2007527851A (en) | Use of kahalalide compounds for the manufacture of a treatment for psoriasis | |
US6596692B1 (en) | Substance P analogs for the treatment of cancer | |
CA2405724C (en) | Substance p analogs for the treatment of cancer | |
KR102499473B1 (en) | A novel family of peptides for the treatment of female sexual dysfunction | |
CZ162294A3 (en) | Peptides with organoprotective activity, process of their preparation and pharmaceutical composition containing thereof | |
JPH07242563A (en) | Cancer metastasis inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UREKA SARL, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZIMMER, ROBERT H.;GUICHARD, GILLES;FREMAUX, JULIETTE;AND OTHERS;SIGNING DATES FROM 20180702 TO 20180709;REEL/FRAME:054774/0280 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |